e10vq
SECURITIES AND EXCHANGE
COMMISSION
Washington, D.C.
20549
Form 10-Q
(Mark One)
|
|
þ
|
QUARTERLY REPORT PURSUANT TO
SECTION 13 OR 15(d) OF THE
SECURITIES EXCHANGE ACT OF 1934
|
For the quarterly period ended June 29, 2008
OR
|
|
o |
TRANSITION REPORT PURSUANT TO
SECTION 13 OR 15(d) OF THE
SECURITIES EXCHANGE ACT OF 1934
|
For the transition period
from
to .
Commission file number 1-5353
TELEFLEX INCORPORATED
(Exact name of registrant as
specified in its charter)
|
|
|
Delaware
|
|
23-1147939
|
(State or other jurisdiction
of
incorporation or organization)
|
|
(I.R.S. employer identification
no.)
|
|
|
|
155 South Limerick Road,
Limerick, Pennsylvania
|
|
19468
|
(Address of principal executive
offices)
|
|
(Zip Code)
|
(610) 948-5100
(Registrants telephone
number, including area code)
(None)
(Former Name, Former Address and
Former Fiscal Year, If Changed Since Last Report)
Indicate by check mark whether the registrant (1) has filed
all reports required to be filed by Section 13 or 15(d) of
the Securities Exchange Act of 1934 during the preceding
12 months (or for such shorter period that the registrant
was required to file such reports), and (2) has been
subject to such filing requirements for the past 90 days.
Yes þ No o
Indicate by check mark whether the registrant is a large
accelerated filer, an accelerated filer, a non-accelerated
filer, or a smaller reporting company. See the definitions of
large accelerated filer, accelerated
filer and smaller reporting company in
Rule 12b-2
of the Exchange Act. (Check one):
|
|
|
|
|
|
|
Large accelerated
filer þ
|
|
Accelerated
filer o
|
|
Non-accelerated
filer o
|
|
Smaller reporting
company o
|
|
|
|
|
(Do not check if a smaller reporting company)
|
|
|
Indicate by check mark whether the registrant is a shell company
(as defined in
Rule 12b-2
of the Act).
Yes o No þ
Indicate the number of shares outstanding of each of the
issuers classes of Common Stock, as of July 21, 2008:
|
|
|
Common Stock, $1.00 Par Value
|
|
39,670,693
|
(Title of each class)
|
|
(Number of shares)
|
TELEFLEX
INCORPORATED
QUARTERLY REPORT ON
FORM 10-Q
FOR THE QUARTER ENDED JUNE 29, 2008
TABLE OF
CONTENTS
|
|
|
|
|
|
|
|
|
|
|
Page
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
2
|
|
|
|
|
|
|
3
|
|
|
|
|
|
|
4
|
|
|
|
|
|
|
5
|
|
|
|
|
|
|
23
|
|
|
|
|
|
|
30
|
|
|
|
|
|
|
30
|
|
|
|
|
|
|
|
|
|
|
|
|
|
31
|
|
|
|
|
|
|
32
|
|
|
|
|
|
|
32
|
|
|
|
|
|
|
32
|
|
|
|
|
|
|
32
|
|
|
|
|
|
|
32
|
|
|
|
|
|
|
33
|
|
|
|
|
|
|
|
|
|
34
|
|
1
PART I
FINANCIAL INFORMATION
|
|
Item 1.
|
Financial
Statements
|
TELEFLEX
INCORPORATED AND SUBSIDIARIES
(Unaudited)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Three Months Ended
|
|
|
Six Months Ended
|
|
|
|
June 29,
|
|
|
July 1,
|
|
|
June 29,
|
|
|
July 1,
|
|
|
|
2008
|
|
|
2007
|
|
|
2008
|
|
|
2007
|
|
|
|
(Dollars and shares in thousands, except per share)
|
|
|
Net revenues
|
|
$
|
624,085
|
|
|
$
|
452,317
|
|
|
$
|
1,228,605
|
|
|
$
|
892,657
|
|
Materials, labor and other product costs
|
|
|
365,436
|
|
|
|
288,987
|
|
|
|
737,101
|
|
|
|
567,879
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Gross profit
|
|
|
258,649
|
|
|
|
163,330
|
|
|
|
491,504
|
|
|
|
324,778
|
|
Selling, engineering and administrative expenses
|
|
|
162,850
|
|
|
|
103,558
|
|
|
|
314,718
|
|
|
|
201,865
|
|
Restructuring and impairment charges
|
|
|
2,591
|
|
|
|
1,081
|
|
|
|
11,447
|
|
|
|
1,522
|
|
Net loss on sales of businesses and assets
|
|
|
|
|
|
|
2,121
|
|
|
|
18
|
|
|
|
1,328
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Income from continuing operations before interest, taxes and
minority interest
|
|
|
93,208
|
|
|
|
56,570
|
|
|
|
165,321
|
|
|
|
120,063
|
|
Interest expense
|
|
|
31,383
|
|
|
|
9,509
|
|
|
|
62,473
|
|
|
|
18,677
|
|
Interest income
|
|
|
(465
|
)
|
|
|
(2,059
|
)
|
|
|
(1,507
|
)
|
|
|
(3,323
|
)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Income from continuing operations before taxes and minority
interest
|
|
|
62,290
|
|
|
|
49,120
|
|
|
|
104,355
|
|
|
|
104,709
|
|
Taxes on income from continuing operations
|
|
|
15,404
|
|
|
|
9,166
|
|
|
|
27,472
|
|
|
|
23,816
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Income from continuing operations before minority interest
|
|
|
46,886
|
|
|
|
39,954
|
|
|
|
76,883
|
|
|
|
80,893
|
|
Minority interest in consolidated subsidiaries, net of tax
|
|
|
9,098
|
|
|
|
6,708
|
|
|
|
16,152
|
|
|
|
13,816
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Income from continuing operations
|
|
|
37,788
|
|
|
|
33,246
|
|
|
|
60,731
|
|
|
|
67,077
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Operating (loss) income from discontinued operations (including
loss on disposal of $4,808 in 2008 and gain on disposal of
$75,490 in 2007, respectively)
|
|
|
(4,808
|
)
|
|
|
93,217
|
|
|
|
(4,808
|
)
|
|
|
110,970
|
|
Taxes (benefit) on income (loss) from discontinued operations
|
|
|
(1,963
|
)
|
|
|
32,602
|
|
|
|
(1,963
|
)
|
|
|
39,912
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
(Loss) income from discontinued operations
|
|
|
(2,845
|
)
|
|
|
60,615
|
|
|
|
(2,845
|
)
|
|
|
71,058
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Net income
|
|
$
|
34,943
|
|
|
$
|
93,861
|
|
|
$
|
57,886
|
|
|
$
|
138,135
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Earnings per share:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Basic:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Income from continuing operations
|
|
$
|
0.96
|
|
|
$
|
0.85
|
|
|
$
|
1.54
|
|
|
$
|
1.71
|
|
(Loss) income from discontinued operations
|
|
|
(0.07
|
)
|
|
|
1.55
|
|
|
|
(0.07
|
)
|
|
|
1.82
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Net income
|
|
$
|
0.88
|
|
|
$
|
2.39
|
|
|
$
|
1.47
|
|
|
$
|
3.53
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Diluted:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Income from continuing operations
|
|
$
|
0.95
|
|
|
$
|
0.84
|
|
|
$
|
1.53
|
|
|
$
|
1.70
|
|
(Loss) income from discontinued operations
|
|
|
(0.07
|
)
|
|
|
1.53
|
|
|
|
(0.07
|
)
|
|
|
1.80
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Net income
|
|
$
|
0.88
|
|
|
$
|
2.37
|
|
|
$
|
1.46
|
|
|
$
|
3.49
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Dividends per share
|
|
$
|
0.34
|
|
|
$
|
0.32
|
|
|
$
|
0.66
|
|
|
$
|
0.605
|
|
Weighted average common shares outstanding:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Basic
|
|
|
39,562
|
|
|
|
39,221
|
|
|
|
39,508
|
|
|
|
39,126
|
|
Diluted
|
|
|
39,831
|
|
|
|
39,678
|
|
|
|
39,770
|
|
|
|
39,540
|
|
The accompanying notes are an integral part of the condensed
consolidated financial statements.
2
TELEFLEX
INCORPORATED AND SUBSIDIARIES
(Unaudited)
|
|
|
|
|
|
|
|
|
|
|
June 29,
|
|
|
December 31,
|
|
|
|
2008
|
|
|
2007
|
|
|
|
(Dollars in thousands)
|
|
|
ASSETS
|
Current assets
|
|
|
|
|
|
|
|
|
Cash and cash equivalents
|
|
$
|
103,242
|
|
|
$
|
201,342
|
|
Accounts receivable, net
|
|
|
361,876
|
|
|
|
341,963
|
|
Inventories
|
|
|
420,365
|
|
|
|
419,188
|
|
Prepaid expenses
|
|
|
28,875
|
|
|
|
31,051
|
|
Income taxes receivable
|
|
|
46,631
|
|
|
|
|
|
Deferred tax assets
|
|
|
50,725
|
|
|
|
12,025
|
|
Assets held for sale
|
|
|
3,204
|
|
|
|
4,241
|
|
|
|
|
|
|
|
|
|
|
Total current assets
|
|
|
1,014,918
|
|
|
|
1,009,810
|
|
Property, plant and equipment, net
|
|
|
428,964
|
|
|
|
430,976
|
|
Goodwill
|
|
|
1,508,797
|
|
|
|
1,502,256
|
|
Intangibles and other assets
|
|
|
1,183,626
|
|
|
|
1,211,172
|
|
Investments in affiliates
|
|
|
28,451
|
|
|
|
26,594
|
|
Deferred tax assets
|
|
|
6,364
|
|
|
|
7,189
|
|
|
|
|
|
|
|
|
|
|
Total assets
|
|
$
|
4,171,120
|
|
|
$
|
4,187,997
|
|
|
|
|
|
|
|
|
|
|
|
LIABILITIES AND SHAREHOLDERS EQUITY
|
Current liabilities
|
|
|
|
|
|
|
|
|
Current borrowings
|
|
$
|
172,491
|
|
|
$
|
185,129
|
|
Accounts payable
|
|
|
150,221
|
|
|
|
133,654
|
|
Accrued expenses
|
|
|
175,211
|
|
|
|
180,110
|
|
Payroll and benefit-related liabilities
|
|
|
79,994
|
|
|
|
84,251
|
|
Income taxes payable
|
|
|
20,673
|
|
|
|
85,805
|
|
Deferred tax liabilities
|
|
|
18,043
|
|
|
|
21,733
|
|
|
|
|
|
|
|
|
|
|
Total current liabilities
|
|
|
616,633
|
|
|
|
690,682
|
|
Long-term borrowings
|
|
|
1,473,545
|
|
|
|
1,499,130
|
|
Deferred tax liabilities
|
|
|
402,518
|
|
|
|
379,467
|
|
Pension and postretirement benefit liabilities
|
|
|
78,694
|
|
|
|
78,910
|
|
Other liabilities
|
|
|
171,181
|
|
|
|
168,782
|
|
|
|
|
|
|
|
|
|
|
Total liabilities
|
|
|
2,742,571
|
|
|
|
2,816,971
|
|
Minority interest in equity of consolidated subsidiaries
|
|
|
34,065
|
|
|
|
42,183
|
|
Commitments and contingencies
|
|
|
|
|
|
|
|
|
Shareholders equity
|
|
|
1,394,484
|
|
|
|
1,328,843
|
|
|
|
|
|
|
|
|
|
|
Total liabilities and shareholders equity
|
|
$
|
4,171,120
|
|
|
$
|
4,187,997
|
|
|
|
|
|
|
|
|
|
|
The accompanying notes are an integral part of the condensed
consolidated financial statements.
3
TELEFLEX
INCORPORATED AND SUBSIDIARIES
(Unaudited)
|
|
|
|
|
|
|
|
|
|
|
Six Months Ended
|
|
|
|
June 29,
|
|
|
July 1,
|
|
|
|
2008
|
|
|
2007
|
|
|
|
(Dollars in thousands)
|
|
|
Cash Flows from Operating Activities of Continuing Operations:
|
|
|
|
|
|
|
|
|
Net income
|
|
$
|
57,886
|
|
|
$
|
138,135
|
|
Adjustments to reconcile net income to net cash provided by
operating activities:
|
|
|
|
|
|
|
|
|
Loss (income) from discontinued operations
|
|
|
2,845
|
|
|
|
(71,058
|
)
|
Depreciation expense
|
|
|
33,711
|
|
|
|
23,391
|
|
Amortization expense of intangible assets
|
|
|
23,587
|
|
|
|
5,725
|
|
Amortization expense of deferred financing costs
|
|
|
2,510
|
|
|
|
560
|
|
Stock-based compensation
|
|
|
4,241
|
|
|
|
4,205
|
|
Net loss on sales of businesses and assets
|
|
|
18
|
|
|
|
1,328
|
|
Minority interest in consolidated subsidiaries
|
|
|
16,152
|
|
|
|
13,816
|
|
Other
|
|
|
978
|
|
|
|
(394
|
)
|
Changes in operating assets and liabilities, net of effects of
acquisitions:
|
|
|
|
|
|
|
|
|
Accounts receivable
|
|
|
(12,911
|
)
|
|
|
(22,746
|
)
|
Inventories
|
|
|
3,132
|
|
|
|
(14,201
|
)
|
Prepaid expenses
|
|
|
5,117
|
|
|
|
1,476
|
|
Accounts payable and accrued expenses
|
|
|
13,338
|
|
|
|
16,387
|
|
Income taxes payable and deferred income taxes
|
|
|
(128,649
|
)
|
|
|
10,367
|
|
|
|
|
|
|
|
|
|
|
Net cash provided by operating activities from continuing
operations
|
|
|
21,955
|
|
|
|
106,991
|
|
|
|
|
|
|
|
|
|
|
Cash Flows from Financing Activities of Continuing Operations:
|
|
|
|
|
|
|
|
|
Proceeds from long-term borrowings
|
|
|
|
|
|
|
20,000
|
|
Repayments of long-term borrowings
|
|
|
(38,983
|
)
|
|
|
(20,154
|
)
|
Decrease in notes payable and current borrowings
|
|
|
(1,340
|
)
|
|
|
(8,425
|
)
|
Proceeds from stock compensation plans
|
|
|
5,586
|
|
|
|
20,459
|
|
Payments to minority interest shareholders
|
|
|
(24,942
|
)
|
|
|
|
|
Dividends
|
|
|
(26,086
|
)
|
|
|
(23,711
|
)
|
|
|
|
|
|
|
|
|
|
Net cash used in financing activities from continuing operations
|
|
|
(85,765
|
)
|
|
|
(11,831
|
)
|
|
|
|
|
|
|
|
|
|
Cash Flows from Investing Activities of Continuing Operations:
|
|
|
|
|
|
|
|
|
Expenditures for property, plant and equipment
|
|
|
(17,805
|
)
|
|
|
(20,540
|
)
|
Payments for businesses acquired
|
|
|
(5,673
|
)
|
|
|
(43,900
|
)
|
Proceeds from sales of businesses and assets
|
|
|
|
|
|
|
143,260
|
|
Purchase of intellectual property
|
|
|
(410
|
)
|
|
|
|
|
Investments in affiliates
|
|
|
(250
|
)
|
|
|
(5,730
|
)
|
|
|
|
|
|
|
|
|
|
Net cash (used in) provided by investing activities from
continuing operations
|
|
|
(24,138
|
)
|
|
|
73,090
|
|
|
|
|
|
|
|
|
|
|
Cash Flows from Discontinued Operations:
|
|
|
|
|
|
|
|
|
Net cash (used in) provided by operating activities
|
|
|
(5,616
|
)
|
|
|
32,919
|
|
Net cash used in financing activities
|
|
|
|
|
|
|
(576
|
)
|
Net cash used in investing activities
|
|
|
|
|
|
|
(8,666
|
)
|
|
|
|
|
|
|
|
|
|
Net cash (used in) provided by discontinued operations
|
|
|
(5,616
|
)
|
|
|
23,677
|
|
|
|
|
|
|
|
|
|
|
Effect of exchange rate changes on cash and cash equivalents
|
|
|
(4,536
|
)
|
|
|
4,332
|
|
|
|
|
|
|
|
|
|
|
Net (decrease) increase in cash and cash equivalents
|
|
|
(98,100
|
)
|
|
|
196,259
|
|
Cash and cash equivalents at the beginning of the period
|
|
|
201,342
|
|
|
|
248,409
|
|
|
|
|
|
|
|
|
|
|
Cash and cash equivalents at the end of the period
|
|
$
|
103,242
|
|
|
$
|
444,668
|
|
|
|
|
|
|
|
|
|
|
The accompanying notes are an integral part of the condensed
consolidated financial statements.
4
TELEFLEX
INCORPORATED AND SUBSIDIARIES
(Unaudited)
|
|
Note 1
|
Basis of
presentation
|
Teleflex Incorporated (the Company) is a diversified
company specializing in the design, manufacture and distribution
of specialty-engineered products. The Company serves a wide
range of customers in segments of the medical, aerospace and
commercial industries. The Companys products include:
devices used in critical care applications, surgical
instruments, and cardiac assist devices for hospitals and
healthcare providers, and instruments and devices delivered to
medical device manufacturers; engine repair products and
services and cargo-handling systems and equipment used in
commercial aircraft; and marine driver controls, and engine
assemblies and drive parts, power and fuel management systems
and rigging products and services for commercial industries.
The accompanying condensed consolidated financial statements of
the Company have been prepared in accordance with accounting
principles generally accepted in the United States of America
(US GAAP) for interim financial information and in
accordance with the instructions for
Form 10-Q
and
Rule 10-01
of
Regulation S-X.
Accordingly, they do not include all information and footnotes
required by US GAAP for complete financial statements.
The accompanying financial information is unaudited; however, in
the opinion of the Companys management, all adjustments
(consisting of normal recurring adjustments and accruals)
necessary for a fair statement of the financial position,
results of operations and cash flows for the periods reported
have been included. The results of operations for the periods
reported are not necessarily indicative of those that may be
expected for a full year.
This quarterly report should be read in conjunction with the
consolidated financial statements and notes thereto included in
the Companys audited consolidated financial statements for
the fiscal year ended December 31, 2007.
Certain reclassifications have been made to the prior year
condensed consolidated financial statements to conform to
current period presentation. Certain financial information is
presented on a rounded basis, which may cause minor differences.
|
|
Note 2
|
New
accounting standards
|
Split-Dollar Life Insurance Arrangements: In
March 2007, the Financial Accounting Standards Board
(FASB) ratified the consensus reached by the
Emerging Issues Task Force (EITF) for Issue
06-10
Accounting for Collateral Assignment Split-Dollar Life
Insurance Arrangements.
EITF 06-10
provides guidance for determining when a liability exists for
the postretirement benefit obligation as well as recognition and
measurement of the associated asset on the basis of the terms of
the collateral assignment agreement.
EITF 06-10
is effective for fiscal years beginning after December 15,
2007. Accordingly, the Company adopted the requirements of
EITF 06-10
on January 1, 2008, as a change in accounting principle
through a cumulative-effect adjustment that reduced retained
earnings by approximately $1.9 million. The adjustment was
determined by assessing the future cash flows of the premiums
that were paid to date as of December 31, 2007 that the
Company is entitled to recover under the split-dollar life
insurance arrangements and reducing other assets by
$1.9 million. Currently, the Company is not making premium
payments on any of these policies nor has it made any premium
payments since 2003.
Fair Value Measurements: In September 2006,
the FASB issued Statement of Financial Accounting Standards
(SFAS) No. 157, Fair Value
Measurements. SFAS No. 157 establishes a common
definition for fair value to be applied to US GAAP that requires
the use of fair value, establishes a framework for measuring
fair value, and expands disclosure about such fair value
measurements. SFAS No. 157 is effective for fiscal
years beginning after November 15, 2007.
In February 2008, the FASB issued FASB Staff Position
(FSP)
157-2
Partial Deferral of the Effective Date of Statement
157.
FSP 157-2
delays the effective date of SFAS No. 157 to fiscal
years beginning after November 15, 2008 for all
nonfinancial assets and nonfinancial liabilities, except those
that are recognized or disclosed at fair value in the financial
statements on a recurring basis (at least annually). The Company
has adopted
5
TELEFLEX
INCORPORATED AND SUBSIDIARIES
NOTES TO
CONDENSED CONSOLIDATED FINANCIAL
STATEMENTS (Continued)
SFAS No. 157 as of January 1, 2008 related to
financial assets and financial liabilities. Refer to
Note 11 for additional discussion on fair value
measurements. The Company is currently evaluating the impact of
SFAS No. 157 related to nonfinancial assets and
nonfinancial liabilities on the Companys financial
position, results of operations and cash flows.
Fair Value Option: In February 2007, the FASB
issued SFAS No. 159, The Fair Value Option for
Financial Assets and Financial Liabilities including
an amendment of FASB Statement No. 115, which permits
an entity to measure certain financial assets and financial
liabilities at fair value, with unrealized gains and losses
reported in earnings at each subsequent measurement date. The
fair value option may be elected on an
instrument-by-instrument
basis, as long as it is applied to the instrument in its
entirety. The fair value option election is irrevocable, unless
an event specified in SFAS No. 159 occurs that results
in a new election date. This statement is effective for fiscal
years beginning after November 15, 2007. The Company
adopted SFAS No. 159 as of January 1, 2008 and
has elected not to measure any additional financial instruments
and other items at fair value.
Business Combinations: In December 2007, the
FASB issued SFAS No. 141(R), Business
Combinations. SFAS No. 141(R) replaces
SFAS No. 141, Business Combinations.
SFAS No. 141(R) retains the fundamental requirements
in Statement 141 that the acquisition method of accounting
(which Statement 141 called the purchase method) be used
for all business combinations and for an acquirer to be
identified for each business combination.
SFAS No. 141(R) defines the acquirer as the entity
that obtains control of one or more businesses in the business
combination and establishes the acquisition date as the date
that the acquirer achieves control.
SFAS No. 141(R)s scope is broader than that of
Statement 141, which applied only to business combinations in
which control was obtained by transferring consideration.
SFAS No. 141(R) replaces Statement 141s
cost-allocation process and requires an acquirer to recognize
the assets acquired, the liabilities assumed, and any
noncontrolling interest in the acquiree at the acquisition date,
measured at their fair values as of that date, with limited
exceptions. In addition, SFAS No. 141(R) changes the
allocation and treatment of acquisition-related costs,
restructuring costs that the acquirer expected but was not
obligated to incur, the recognition of assets and liabilities
assumed arising from contingencies and the recognition and
measurement of goodwill. This statement is effective for fiscal
years beginning after December 15, 2008 and is to be
applied prospectively to business combinations. Accordingly, the
Company will apply the provisions of SFAS No. 141(R)
upon adoption on its effective date.
Noncontrolling Interests: In December 2007,
the FASB issued SFAS No. 160, Noncontrolling
Interests in Consolidated Financial Statements an
amendment of ARB No. 51. SFAS No. 160
amends ARB 51 to establish accounting and reporting standards
for the noncontrolling interest in a subsidiary, sometimes
referred to as minority interest, and for the deconsolidation of
a subsidiary. It clarifies that a noncontrolling interest in a
subsidiary is an ownership interest in the consolidated entity
that should be reported as equity in the consolidated financial
statements. SFAS No. 160 requires that a
noncontrolling interest in subsidiaries held by parties other
than the parent be clearly identified, labeled, and presented in
the consolidated statement of financial position within equity,
but separate from the parents equity, that the amount of
consolidated net income attributable to the parent and to the
noncontrolling interest be clearly identified and presented on
the face of the consolidated statement of income, that the
changes in a parents ownership interest while the parent
retains its controlling financial interest in its subsidiary be
accounted for consistently as equity transactions and that when
a subsidiary is deconsolidated, any retained noncontrolling
equity investment in the former subsidiary be initially measured
at fair value. This statement is effective for fiscal years
beginning after December 15, 2008 and earlier adoption is
prohibited. Accordingly, the Company will apply the provisions
of SFAS No. 160 upon adoption on its effective date.
Disclosures about Derivative Instruments and Hedging
Activities: In March 2008, the FASB issued
SFAS No. 161 Disclosures about Derivative
Instruments and Hedging Activities an amendment of
FASB Statement No. 133, which requires enhanced
disclosures about derivative and hedging activities. Companies
will be required to provide enhanced disclosures about
(a) how and why a company uses derivative instruments,
(b) how derivative instruments and related hedged items are
accounted for under Statement 133 and related interpretations,
6
TELEFLEX
INCORPORATED AND SUBSIDIARIES
NOTES TO
CONDENSED CONSOLIDATED FINANCIAL
STATEMENTS (Continued)
and (c) how derivative instruments and related hedged items
affect the companys financial position, financial
performance, and cash flows. SFAS No. 161 is effective
for financial statements issued for fiscal and interim periods
beginning after November 15, 2008. Accordingly, the Company
will ensure that it meets the enhanced disclosure provisions of
SFAS No. 161 upon the effective date.
Hierarchy of Generally Accepted Accounting
Principles: In May 2008, the FASB issued
SFAS No. 162 The Hierarchy of Generally Accepted
Accounting Principles, which has been established by the
FASB as a framework for entities to identify the sources of
accounting principles and the framework for selecting the
principles to be used in the preparation of financial statements
of nongovernmental entities that are presented in conformity
with US GAAP. SFAS No. 162 is not expected to
result in a change in current practices. SFAS No. 162
is effective 60 days following the Securities and Exchange
Commissions (SEC) approval of the Public
Company Accounting Oversight Boards (PCAOB)
amendments to AU Section 411, The Meaning of Present
Fairly in Conformity With Generally Accepted Accounting
Principles. Accordingly, the Company will adopt
SFAS No. 162 within the required period.
Determining Whether Instruments Granted in Share-Based
Payment Transactions Are Participating Securities:
In June 2008, the FASB issued FSP
EITF 03-6-1
Determining Whether Instruments Granted in Share-Based
Payment Transactions Are Participating Securities, which
addresses whether unvested instruments granted in share-based
payment transactions that contain nonforfeitable rights to
dividends or dividend equivalents are participating securities
subject to the two-class method of computing earnings per share
under SFAS No. 128, Earnings Per Share.
FSP
EITF 03-6-1
is effective for financial statements issued for fiscal years
beginning after December 15, 2008 and interim periods
within those years. The Company is currently evaluating the
guidance under FSP
EITF 03-6-1
but does not expect it will result in a change in the manner the
Company currently presents its Earnings Per Share.
Acquisition
of Arrow International, Inc.
On October 1, 2007, the Company acquired all of the
outstanding capital stock of Arrow International, Inc.
(Arrow) for approximately $2.1 billion. Arrow
is a global provider of catheter-based access and therapeutic
products for critical and cardiac care. The transaction was
financed with cash, borrowings under a new senior secured
syndicated bank loan and proceeds received through the issuance
of privately placed notes. The results of operations for Arrow
are included in the Companys Medical Segment from the date
of acquisition.
Under the terms of the transaction, the Company paid $45.50 per
common share in cash, or $2,094.6 million in total, to
acquire all of the outstanding common shares of Arrow. In
addition, the Company paid $39.1 million in cash for
outstanding stock options of Arrow. Pursuant to the terms of the
agreement, upon the change in control of Arrow, Arrows
outstanding stock options became fully vested and exercisable
and were cancelled in exchange for the right to receive an
amount for each share subject to the stock option equal to the
excess of $45.50 per share over the exercise price per share of
each option. The aggregate purchase price of
$2,104.0 million includes transaction costs of
approximately $10.8 million.
In conjunction with the acquisition of Arrow, the Company repaid
approximately $35.1 million of debt, representing
substantially all of Arrows existing outstanding debt as
of October 1, 2007.
The Company financed the all cash purchase price and related
transaction costs associated with the Arrow acquisition and the
repayment of substantially all of Arrows outstanding debt
with $1,672.0 million from borrowings under a new senior
secured syndicated bank loan and proceeds received through the
issuance of privately placed notes and cash on hand of
approximately $433.5 million.
7
TELEFLEX
INCORPORATED AND SUBSIDIARIES
NOTES TO
CONDENSED CONSOLIDATED FINANCIAL
STATEMENTS (Continued)
The acquisition of Arrow was accounted for under the purchase
method of accounting. As such, the cost to acquire Arrow was
allocated to the respective assets and liabilities acquired
based on their preliminary estimated fair values as of the
closing date.
The following table summarizes the revised purchase price
allocation of the cost to acquire Arrow based on the preliminary
fair values as of October 1, 2007:
|
|
|
|
|
|
|
(Dollars in millions)
|
|
|
Assets
|
|
|
|
|
Current assets
|
|
$
|
401.4
|
|
Property, plant and equipment
|
|
|
184.1
|
|
Intangible assets
|
|
|
930.4
|
|
Goodwill
|
|
|
1,041.4
|
|
Other assets
|
|
|
45.8
|
|
|
|
|
|
|
Total assets acquired
|
|
$
|
2,603.1
|
|
|
|
|
|
|
Less:
|
|
|
|
|
Current liabilities
|
|
$
|
126.6
|
|
Deferred tax liabilities
|
|
|
330.8
|
|
Other long-term liabilities
|
|
|
41.7
|
|
|
|
|
|
|
Liabilities assumed
|
|
$
|
499.1
|
|
|
|
|
|
|
Net assets acquired
|
|
$
|
2,104.0
|
|
|
|
|
|
|
The Company is continuing to evaluate the initial purchase price
allocation as of the acquisition date, which will be adjusted as
additional information related to the fair values of assets
acquired and liabilities assumed becomes known.
Certain assets acquired in the Arrow merger qualify for
recognition as intangible assets apart from goodwill in
accordance with SFAS No. 141, Business
Combinations. The preliminary estimated fair value of
intangible assets acquired included customer related intangibles
of $497.7 million, trade names of $249.0 million and
purchased technology of $153.4 million. Customer related
intangibles have a useful life of 25 years and purchased
technology have useful lives ranging from 7-15 years. Trade
names have an indefinite useful life. A portion of the purchase
price allocation, $30 million, representing in-process
research and development was deemed to have no future
alternative use and was charged to expense as of the date of the
combination. Goodwill is not deductible for tax purposes.
8
TELEFLEX
INCORPORATED AND SUBSIDIARIES
NOTES TO
CONDENSED CONSOLIDATED FINANCIAL
STATEMENTS (Continued)
Pro Forma
Combined Financial Information
The following unaudited pro forma combined financial information
for the three and six months ended July 1, 2007 gives
effect to the Arrow merger as if it was completed at the
beginning of the period.
|
|
|
|
|
|
|
|
|
|
|
Three Months Ended
|
|
|
Six Months Ended
|
|
|
|
(Dollars in thousands, except per share amounts)
|
|
|
Net revenue
|
|
$
|
582,813
|
|
|
$
|
1,148,622
|
|
Income (loss) from continuing operations
|
|
$
|
15,246
|
|
|
$
|
(10,937
|
)
|
Net income
|
|
$
|
75,861
|
|
|
$
|
60,121
|
|
Basic earnings per common share:
|
|
|
|
|
|
|
|
|
Income (loss) from continuing operations
|
|
$
|
0.39
|
|
|
$
|
(0.28
|
)
|
Net income
|
|
$
|
1.93
|
|
|
$
|
1.54
|
|
Diluted earnings per common share:
|
|
|
|
|
|
|
|
|
Income (loss) from continuing operations
|
|
$
|
0.38
|
|
|
$
|
(0.28
|
)
|
Net income
|
|
$
|
1.91
|
|
|
$
|
1.54
|
|
Weighted average common shares outstanding:
|
|
|
|
|
|
|
|
|
Basic
|
|
|
39,221
|
|
|
|
39,126
|
|
Diluted
|
|
|
39,678
|
|
|
|
39,126
|
|
The unaudited pro forma combined financial information presented
above includes special charges in the three and six month
periods of $6.9 million and $35.8 million,
respectively, of inventory
step-up. In
addition, the six month period includes special charges of
$30.0 million for the in-process research and development
write-off that is charged to expense as of the date of the
combination and the $1.0 million financing costs paid to
third parties for the amended notes.
Integration
of Arrow
In connection with the acquisition of Arrow, the Company
formulated a plan related to the future integration of Arrow and
the Companys Medical businesses. The integration plan
focuses on the closure of Arrow corporate functions and the
consolidation of manufacturing, sales, marketing and
distribution functions in North America, Europe and Asia. The
Company does not expect the finalization of these programs to
result in a material adjustment to the estimated costs to
implement the plan.
9
TELEFLEX
INCORPORATED AND SUBSIDIARIES
NOTES TO
CONDENSED CONSOLIDATED FINANCIAL
STATEMENTS (Continued)
The Company recognized an initial amount of $31.6 million
as a liability assumed in the acquisition of Arrow, and included
in the allocation of the purchase price, for the estimated costs
to carry out the integration plan. Of this amount,
$18.4 million relates to employee termination costs,
$3.6 million to facility closure costs, and
$9.6 million to termination of certain distribution
agreements and other actions. The Company continues to evaluate
and adjust the Arrow integration plan. The activity, including
changes in estimates to the integration cost accrual from
December 31, 2007 through June 29, 2008 are as follows:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Involuntary
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Employee
|
|
|
|
|
|
Contract
|
|
|
Other
|
|
|
|
|
|
|
Termination
|
|
|
Facility
|
|
|
Termination
|
|
|
Restructuring
|
|
|
|
|
|
|
Benefits
|
|
|
Closure Costs
|
|
|
Costs
|
|
|
Costs
|
|
|
Total
|
|
|
|
(Dollars in millions)
|
|
|
Balance at December 31, 2007
|
|
$
|
14.8
|
|
|
$
|
3.6
|
|
|
$
|
9.6
|
|
|
$
|
|
|
|
$
|
28.0
|
|
Cash payments
|
|
|
(4.8
|
)
|
|
|
|
|
|
|
(0.3
|
)
|
|
|
(0.1
|
)
|
|
|
(5.2
|
)
|
Adjustments to reserve
|
|
|
(1.0
|
)
|
|
|
(3.1
|
)
|
|
|
1.9
|
|
|
|
0.5
|
|
|
|
(1.7
|
)
|
Foreign currency translation
|
|
|
0.4
|
|
|
|
0.2
|
|
|
|
1.0
|
|
|
|
|
|
|
|
1.6
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Balance at June 29, 2008
|
|
$
|
9.4
|
|
|
$
|
0.7
|
|
|
$
|
12.2
|
|
|
$
|
0.4
|
|
|
$
|
22.7
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
It is anticipated that a majority of the balance of these costs
will be charged to the reserve in 2008; however, it is currently
projected that the costs for some portions of the manufacturing
integration will be charged to the reserve through the third
quarter of 2010.
In conjunction with the plan for the integration of Arrow and
the Companys Medical businesses, the Company expects to
take actions that affect employees and facilities of Teleflex.
This aspect of the integration plan is explained in Note 4
Restructuring and such costs incurred will be
charged to earnings and included in restructuring and
impairment charges within the condensed consolidated
statement of operations.
Acquisition
of Nordisk Aviation Products
In November 2007, the company acquired Nordisk Aviation Products
a.s. (Nordisk), a world leader in developing, supplying and
servicing containers and pallets for air cargo, for
approximately $27.8 million, net of cash acquired. The
results of Nordisk are included in the Companys Aerospace
Segment. Revenues for the three and six month periods ending
June 29, 2008 were $12.9 million and
$26.4 million, respectively.
Acquisition
of Specialized Medical Devices, Inc.
In April 2007, the Company acquired the assets of HDJ Company,
Inc. (HDJ) and its wholly owned subsidiary,
Specialized Medical Devices, Inc. (SMD), a provider
of engineering and manufacturing services to medical device
manufacturers, for approximately $25.0 million. The results
for HDJ are included in the Companys Medical Segment.
Revenues for the three and six month periods ending
June 29, 2008 were $3.5 million and $7.3 million,
respectively.
Acquisition
of Southern Wire Corporation.
In April 2007, the Company acquired substantially all of the
assets of Southern Wire Corporation (Southern Wire),
a wholesale distributor of wire rope cables and related
hardware, for approximately $20.6 million. The results for
Southern Wire are included in the Companys Commercial
Segment. Revenues for the three and six month periods
ending June 29, 2008 were $10.5 million and
$19.5 million, respectively.
10
TELEFLEX
INCORPORATED AND SUBSIDIARIES
NOTES TO
CONDENSED CONSOLIDATED FINANCIAL
STATEMENTS (Continued)
The amounts recognized in restructuring and impairment charges
for the three and six month periods ended June 29, 2008 and
July 1, 2007 consisted of the following:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Three Months Ended
|
|
|
Six Months Ended
|
|
|
|
June 29,
|
|
|
July 1,
|
|
|
June 29,
|
|
|
July 1,
|
|
|
|
2008
|
|
|
2007
|
|
|
2008
|
|
|
2007
|
|
|
|
(Dollars in thousands)
|
|
|
2007 Arrow integration program
|
|
$
|
2,734
|
|
|
$
|
|
|
|
$
|
10,780
|
|
|
$
|
|
|
2006 restructuring program
|
|
|
(143
|
)
|
|
|
849
|
|
|
|
667
|
|
|
|
920
|
|
Aerospace Segment restructuring activity
|
|
|
|
|
|
|
(3
|
)
|
|
|
|
|
|
|
(3
|
)
|
2004 restructuring and divestiture program
|
|
|
|
|
|
|
235
|
|
|
|
|
|
|
|
605
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Restructuring and impairment charges
|
|
$
|
2,591
|
|
|
$
|
1,081
|
|
|
$
|
11,447
|
|
|
$
|
1,522
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
2007
Arrow Integration Program
In connection with the acquisition of Arrow, the Company
formulated a plan related to the future integration of Arrow and
the Companys Medical businesses. The integration plan
focuses on the closure of Arrow corporate functions and the
consolidation of manufacturing, sales, marketing and
distribution functions in North America, Europe and Asia. In as
much as the actions affect employees and facilities of Arrow,
the resultant costs have been included in the allocation of the
purchase price of Arrow. Costs related to actions that affect
employees and facilities of Teleflex will be charged to earnings
and included in restructuring and impairment charges
within the consolidated statement of operations. As of
June 29, 2008, the Company estimates that the aggregate of
future restructuring and impairment charges that it will incur
are approximately $18.4 $21.4 million when
actions are taken or costs are incurred in 2008 and 2009 in
connection with this plan. Of this amount, $6.4
$7.4 million relates to employee termination costs,
$10.5 $11.5 million relates to costs associated
with the termination of leases and certain distribution
agreements and $1.5 $2.5 million relates to
other restructuring costs.
The charges associated with the 2007 Arrow integration program
that are included in restructuring and impairment charges for
the three and six month periods ended June 29, 2008 were as
follows:
|
|
|
|
|
|
|
|
|
|
|
Three Months Ended
|
|
|
Six Months Ended
|
|
|
|
June 29, 2008
|
|
|
June 29, 2008
|
|
|
|
Medical
|
|
|
|
(Dollars in thousands)
|
|
|
Termination benefits
|
|
$
|
1,792
|
|
|
$
|
9,838
|
|
Contract termination costs
|
|
|
806
|
|
|
|
806
|
|
Other restructuring costs
|
|
|
136
|
|
|
|
136
|
|
|
|
|
|
|
|
|
|
|
|
|
$
|
2,734
|
|
|
$
|
10,780
|
|
|
|
|
|
|
|
|
|
|
11
TELEFLEX
INCORPORATED AND SUBSIDIARIES
NOTES TO
CONDENSED CONSOLIDATED FINANCIAL
STATEMENTS (Continued)
At June 29, 2008, the accrued liability associated with the
2007 Arrow integration program consisted of the following:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Balance at
|
|
|
|
|
|
|
|
|
|
|
|
Balance at
|
|
|
|
December 31,
|
|
|
Subsequent
|
|
|
|
|
|
|
|
|
June 29,
|
|
|
|
2007
|
|
|
Accruals
|
|
|
Payments
|
|
|
Translation
|
|
|
2008
|
|
|
|
(Dollars in thousands)
|
|
|
Termination benefits
|
|
$
|
606
|
|
|
$
|
9,838
|
|
|
$
|
(2,659
|
)
|
|
$
|
19
|
|
|
$
|
7,804
|
|
Contract termination costs
|
|
|
|
|
|
|
806
|
|
|
|
(152
|
)
|
|
|
|
|
|
|
654
|
|
Other restructuring costs
|
|
|
|
|
|
|
136
|
|
|
|
(16
|
)
|
|
|
|
|
|
|
120
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
$
|
606
|
|
|
$
|
10,780
|
|
|
$
|
(2,827
|
)
|
|
$
|
19
|
|
|
$
|
8,578
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
2006
Restructuring Program
In June 2006, the Company began certain restructuring
initiatives that affected all three of the Companys
reporting segments. These initiatives involved the consolidation
of operations and a related reduction in workforce at several of
the Companys facilities in Europe and North America. The
Company determined to undertake these initiatives to improve
operating performance and to better leverage the Companys
existing resources.
For the three and six month periods ended June 29, 2008 and
July 1, 2007, the charges, including changes in estimates,
associated with the 2006 restructuring program by segment that
are included in restructuring and impairment charges were as
follows:
|
|
|
|
|
|
|
|
|
|
|
Three Months Ended
|
|
|
Six Months Ended
|
|
|
|
June 29, 2008
|
|
|
June 29, 2008
|
|
|
|
Medical
|
|
|
|
(Dollars in thousands)
|
|
|
Termination benefits
|
|
$
|
(182
|
)
|
|
$
|
589
|
|
Contract termination costs
|
|
|
39
|
|
|
|
78
|
|
|
|
|
|
|
|
|
|
|
|
|
$
|
(143
|
)
|
|
$
|
667
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Three Months Ended
|
|
|
|
July 1, 2007
|
|
|
|
Medical
|
|
|
Aerospace
|
|
|
Total
|
|
|
|
(Dollars in thousands)
|
|
|
Termination benefits
|
|
$
|
533
|
|
|
$
|
190
|
|
|
$
|
723
|
|
Contract termination costs
|
|
|
91
|
|
|
|
|
|
|
|
91
|
|
Other restructuring costs
|
|
|
35
|
|
|
|
|
|
|
|
35
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
$
|
659
|
|
|
$
|
190
|
|
|
$
|
849
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Six Months Ended
|
|
|
|
July 1, 2007
|
|
|
|
Medical
|
|
|
Aerospace
|
|
|
Total
|
|
|
|
(Dollars in thousands)
|
|
|
Termination benefits
|
|
$
|
715
|
|
|
$
|
79
|
|
|
$
|
794
|
|
Contract termination costs
|
|
|
91
|
|
|
|
|
|
|
|
91
|
|
Other restructuring costs
|
|
|
35
|
|
|
|
|
|
|
|
35
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
$
|
841
|
|
|
$
|
79
|
|
|
$
|
920
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
12
TELEFLEX
INCORPORATED AND SUBSIDIARIES
NOTES TO
CONDENSED CONSOLIDATED FINANCIAL
STATEMENTS (Continued)
Termination benefits are comprised of severance-related payments
for all employees terminated in connection with the 2006
restructuring program. Contract termination costs relate
primarily to the termination of leases in conjunction with the
consolidation of facilities.
At June 29, 2008, the accrued liability associated with the
2006 restructuring program consisted of the following:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Balance at
|
|
|
|
|
|
|
|
|
|
|
|
Balance at
|
|
|
|
December 31,
|
|
|
Subsequent
|
|
|
|
|
|
|
|
|
June 29,
|
|
|
|
2007
|
|
|
Accruals
|
|
|
Payments
|
|
|
Translation
|
|
|
2008
|
|
|
|
(Dollars in thousands)
|
|
|
Termination benefits
|
|
$
|
1,217
|
|
|
$
|
589
|
|
|
$
|
(1,509
|
)
|
|
$
|
(11
|
)
|
|
$
|
286
|
|
Contract termination costs
|
|
|
561
|
|
|
|
78
|
|
|
|
(236
|
)
|
|
|
|
|
|
|
403
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
$
|
1,778
|
|
|
$
|
667
|
|
|
$
|
(1,745
|
)
|
|
$
|
(11
|
)
|
|
$
|
689
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
The termination benefits set forth above are due within twelve
months.
As of June 29, 2008, the Company expects to incur future
restructuring expenses related to contract terminations of
approximately $266 thousand.
2004
Restructuring and Divestiture Program
During the fourth quarter of 2004, the Company announced and
commenced implementation of a restructuring and divestiture
program designed to improve future operating performance and
position the Company for future earnings growth. The actions
included exiting or divesting of non-core or low performing
businesses, consolidating manufacturing operations and
reorganizing administrative functions to enable businesses to
share services.
No costs were incurred during the three and six month periods
ending June 29, 2008. For the three and six month periods
ended July 1, 2007 the costs, including changes in
estimates, associated with the 2004 restructuring and
divestiture program were incurred by the Companys Medical
Segment and are included in restructuring and impairment charges
as follows:
|
|
|
|
|
|
|
|
|
|
|
Three Months Ended
|
|
Six Months Ended
|
|
|
July 1, 2007
|
|
July 1, 2007
|
|
|
(Dollars in thousands)
|
|
Other restructuring costs
|
|
$
|
235
|
|
|
$
|
605
|
|
|
|
|
|
|
|
|
|
|
|
|
$
|
235
|
|
|
$
|
605
|
|
|
|
|
|
|
|
|
|
|
Other restructuring costs include expenses primarily related to
the consolidation of manufacturing operations and the
reorganization of administrative functions.
At June 29, 2008, the accrued liability associated with the
2004 restructuring program consisted of the following:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Subsequent
|
|
|
|
|
|
|
|
|
|
Balance at
|
|
|
Accruals and
|
|
|
|
|
|
Balance at
|
|
|
|
December 31,
|
|
|
Changes in
|
|
|
|
|
|
June 29,
|
|
|
|
2007
|
|
|
Estimates
|
|
|
Payments
|
|
|
2008
|
|
|
|
(Dollars in thousands)
|
|
|
Termination benefits
|
|
$
|
25
|
|
|
$
|
|
|
|
$
|
(25
|
)
|
|
$
|
|
|
Contract termination costs
|
|
|
1,187
|
|
|
|
|
|
|
|
(347
|
)
|
|
|
840
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
$
|
1,212
|
|
|
$
|
|
|
|
$
|
(372
|
)
|
|
$
|
840
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
As of June 29, 2008 the Company does not expect to incur
additional restructuring expenses associated with the 2004
restructuring and divestiture program.
13
TELEFLEX
INCORPORATED AND SUBSIDIARIES
NOTES TO
CONDENSED CONSOLIDATED FINANCIAL
STATEMENTS (Continued)
Inventories consisted of the following:
|
|
|
|
|
|
|
|
|
|
|
June 29,
|
|
|
December 31,
|
|
|
|
2008
|
|
|
2007
|
|
|
|
(Dollars in thousands)
|
|
|
Raw materials
|
|
$
|
181,021
|
|
|
$
|
179,560
|
|
Work-in-process
|
|
|
74,849
|
|
|
|
61,912
|
|
Finished goods
|
|
|
205,301
|
|
|
|
213,631
|
|
|
|
|
|
|
|
|
|
|
|
|
|
461,171
|
|
|
|
455,103
|
|
Less: Inventory reserve
|
|
|
(40,806
|
)
|
|
|
(35,915
|
)
|
|
|
|
|
|
|
|
|
|
Inventories
|
|
$
|
420,365
|
|
|
$
|
419,188
|
|
|
|
|
|
|
|
|
|
|
|
|
Note 6
|
Goodwill
and other intangible assets
|
Changes in the carrying amount of goodwill, by operating
segment, for the six months ended June 29, 2008 are as
follows:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Medical
|
|
|
Aerospace
|
|
|
Commercial
|
|
|
Total
|
|
|
|
(Dollars in thousands)
|
|
|
Goodwill at December 31, 2007
|
|
$
|
1,452,894
|
|
|
$
|
6,317
|
|
|
$
|
43,045
|
|
|
$
|
1,502,256
|
|
Adjustment to acquisition balance
sheet(1)
|
|
|
(369
|
)
|
|
|
|
|
|
|
|
|
|
|
(369
|
)
|
Translation adjustment
|
|
|
6,837
|
|
|
|
|
|
|
|
73
|
|
|
|
6,910
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Goodwill at June 29, 2008
|
|
$
|
1,459,362
|
|
|
$
|
6,317
|
|
|
$
|
43,118
|
|
|
$
|
1,508,797
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
(1) |
|
See Note 3 Acquisitions |
Intangible assets consisted of the following:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Gross Carrying Amount
|
|
|
Accumulated Amortization
|
|
|
|
June 29,
|
|
|
December 31,
|
|
|
June 29,
|
|
|
December 31,
|
|
|
|
2008
|
|
|
2007
|
|
|
2008
|
|
|
2007
|
|
|
|
(Dollars in thousands)
|
|
|
Customer lists
|
|
$
|
569,249
|
|
|
$
|
568,701
|
|
|
$
|
36,781
|
|
|
$
|
23,643
|
|
Intellectual property
|
|
|
230,805
|
|
|
|
229,325
|
|
|
|
49,022
|
|
|
|
39,100
|
|
Distribution rights
|
|
|
28,486
|
|
|
|
28,139
|
|
|
|
17,309
|
|
|
|
16,437
|
|
Trade names
|
|
|
341,674
|
|
|
|
338,834
|
|
|
|
612
|
|
|
|
311
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
$
|
1,170,214
|
|
|
$
|
1,164,999
|
|
|
$
|
103,724
|
|
|
$
|
79,491
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Amortization expense related to intangible assets was
approximately $11.8 million and $2.9 million for the
three months ended and $23.6 million and $5.7 million
for the six months ended June 29, 2008 and July 1,
2007, respectively. Estimated annual amortization expense for
each of the five succeeding years is as follows (dollars in
thousands):
|
|
|
|
|
2008
|
|
$
|
47,000
|
|
2009
|
|
|
46,800
|
|
2010
|
|
|
46,700
|
|
2011
|
|
|
46,400
|
|
2012
|
|
|
45,200
|
|
14
TELEFLEX
INCORPORATED AND SUBSIDIARIES
NOTES TO
CONDENSED CONSOLIDATED FINANCIAL
STATEMENTS (Continued)
|
|
Note 7
|
Comprehensive
income
|
The following table summarizes the components of comprehensive
income:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Three Months Ended
|
|
|
Six Months Ended
|
|
|
|
June 29,
|
|
|
July 1,
|
|
|
June 29,
|
|
|
July 1,
|
|
|
|
2008
|
|
|
2007
|
|
|
2008
|
|
|
2007
|
|
|
|
(Dollars in thousands)
|
|
|
Net income
|
|
$
|
34,943
|
|
|
$
|
93,861
|
|
|
$
|
57,886
|
|
|
$
|
138,135
|
|
Net unrealized gains (loss) on qualifying cash flow hedges
|
|
|
11,473
|
|
|
|
1,544
|
|
|
|
(168
|
)
|
|
|
2,407
|
|
Changes in pension and postretirement obligations
|
|
|
891
|
|
|
|
|
|
|
|
526
|
|
|
|
|
|
Pension curtailment
|
|
|
|
|
|
|
1,484
|
|
|
|
|
|
|
|
1,484
|
|
Cumulative translation adjustment
|
|
|
(1,171
|
)
|
|
|
9,829
|
|
|
|
24,850
|
|
|
|
14,587
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Comprehensive income
|
|
$
|
46,136
|
|
|
$
|
106,718
|
|
|
$
|
83,094
|
|
|
$
|
156,613
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Note 8
|
Changes
in shareholders equity
|
Set forth below is a reconciliation of the Companys issued
common shares:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Three Months Ended
|
|
|
Six Months Ended
|
|
|
|
June 29,
|
|
|
July 1,
|
|
|
June 29,
|
|
|
July 1,
|
|
|
|
2008
|
|
|
2007
|
|
|
2008
|
|
|
2007
|
|
|
|
(Shares in thousands)
|
|
|
Common shares, beginning of period
|
|
|
41,870
|
|
|
|
41,450
|
|
|
|
41,794
|
|
|
|
41,364
|
|
Shares issued under compensation plans
|
|
|
62
|
|
|
|
244
|
|
|
|
138
|
|
|
|
330
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Common shares, end of period
|
|
|
41,932
|
|
|
|
41,694
|
|
|
|
41,932
|
|
|
|
41,694
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
On June 14, 2007, the Companys Board of Directors
authorized the repurchase of up to $300 million of
outstanding Company common stock. Repurchases of Company stock
under the Board authorization may be made from time to time in
the open market and may include privately-negotiated
transactions as market conditions warrant and subject to
regulatory considerations. The stock repurchase program has no
expiration date, and the Companys ability to execute on
the program will depend on, among other factors, cash
requirements for acquisitions, cash generation from operations,
debt repayment obligations, market conditions and regulatory
requirements. In addition, under the senior loan agreements
entered into October 1, 2007, the Company is subject to
certain restrictions relating to its ability to repurchase
shares in the event the Companys consolidated leverage
ratio exceeds certain levels, which may further limit the
Companys ability to repurchase shares under this Board
authorization. Through June 29, 2008, no shares have been
purchased under this Board authorization.
15
TELEFLEX
INCORPORATED AND SUBSIDIARIES
NOTES TO
CONDENSED CONSOLIDATED FINANCIAL
STATEMENTS (Continued)
Basic earnings per share is computed by dividing net income by
the weighted average number of common shares outstanding during
the period. Diluted earnings per share is computed in the same
manner except that the weighted average number of shares is
increased for dilutive securities. The difference between basic
and diluted weighted average common shares results from the
assumption that dilutive share-based payment awards were
exercised or vested at the beginning of the period. A
reconciliation of basic to diluted weighted average shares
outstanding is as follows:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Three Months Ended
|
|
|
Six Months Ended
|
|
|
|
June 29,
|
|
|
July 1,
|
|
|
June 29,
|
|
|
July 1,
|
|
|
|
2008
|
|
|
2007
|
|
|
2008
|
|
|
2007
|
|
|
|
(Shares in thousands)
|
|
|
Basic
|
|
|
39,562
|
|
|
|
39,221
|
|
|
|
39,508
|
|
|
|
39,126
|
|
Dilutive shares assumed issued
|
|
|
269
|
|
|
|
457
|
|
|
|
262
|
|
|
|
414
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Diluted
|
|
|
39,831
|
|
|
|
39,678
|
|
|
|
39,770
|
|
|
|
39,540
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Weighted average stock options that were anti-dilutive and
therefore not included in the calculation of earnings per share
were approximately 1,119 thousand and 1,029 thousand for the
three and six month periods ended June 29, 2008 and
approximately 326 thousand and 560 thousand for the three and
six month periods ended July 1, 2007, respectively.
|
|
Note 9
|
Stock
compensation plans
|
The Company has two stock-based compensation plans under which
equity-based awards may be made. The Companys 2000 Stock
Compensation Plan (the 2000 plan) provides for the
granting of incentive and non-qualified stock options and
restricted stock units to directors, officers and key employees.
Under the 2000 plan, the Company is authorized to issue up to
4 million shares of common stock, but no more than 800,000
of those shares may be issued as restricted stock. Options
granted under the 2000 plan have an exercise price equal to the
average of the high and low sales prices of the Companys
common stock on the date of the grant, rounded to the nearest
$0.25. Generally, options granted under the 2000 plan are
exercisable three to five years after the date of the grant and
expire no more than ten years after the grant. Outstanding
restricted stock units generally vest in one to three years.
During the first six months of 2008, under the 2000 plan, the
Company granted incentive and non-qualified options to purchase
381,881 shares of common stock and granted restricted stock
units representing 154,468 shares of common stock.
The Companys 2008 Stock Incentive Plan (the 2008
plan) provides for the granting of various types of
equity-based awards to directors, officers and key employees.
These awards include incentive and non-qualified stock options,
stock appreciation rights, stock awards and other stock-based
awards. Under the 2008 plan, the Company is authorized to issue
up to 2.5 million shares of common stock, provided, that
grants of awards other than stock options and stock appreciation
rights may not exceed 875,000 shares. Options granted under
the 2008 plan will have an exercise price equal to the closing
price of the Companys common stock on the date of grant.
The 2008 plan was approved by the Companys stockholders on
May 1, 2008 at the Companys annual meeting of
stockholders. During the first six months of 2008, no awards
have been granted under the 2008 plan.
|
|
Note 10
|
Pension
and other postretirement benefits
|
The Company has a number of defined benefit pension and
postretirement plans covering eligible U.S. and
non-U.S. employees.
The defined benefit pension plans are noncontributory. The
benefits under these plans are based primarily on years of
service and employees pay near retirement. The benefits
under the U.S. defined benefit pension plans are no longer
available to new employees with certain exceptions. The
Companys funding policy for U.S. plans is to
contribute annually, at a minimum, amounts required by
applicable laws and regulations. Obligations under
non-U.S. plans
are systematically provided for by depositing funds with
trustees or by book reserves.
16
TELEFLEX
INCORPORATED AND SUBSIDIARIES
NOTES TO
CONDENSED CONSOLIDATED FINANCIAL
STATEMENTS (Continued)
The Company and certain of its subsidiaries provide medical,
dental and life insurance benefits to pensioners and survivors.
The associated plans are unfunded and approved claims are paid
from Company funds.
Net benefit cost of pension and postretirement benefit plans
consisted of the following:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Pension
|
|
|
Other Benefits
|
|
|
Pension
|
|
|
Other Benefits
|
|
|
|
Three Months Ended
|
|
|
Three Months Ended
|
|
|
Six Months Ended
|
|
|
Six Months Ended
|
|
|
|
June 29,
|
|
|
July 1,
|
|
|
June 29,
|
|
|
July 1,
|
|
|
June 29,
|
|
|
July 1,
|
|
|
June 29,
|
|
|
July 1,
|
|
|
|
2008
|
|
|
2007
|
|
|
2008
|
|
|
2007
|
|
|
2008
|
|
|
2007
|
|
|
2008
|
|
|
2007
|
|
|
|
(Dollars in thousands)
|
|
|
Service cost
|
|
$
|
1,330
|
|
|
$
|
904
|
|
|
$
|
247
|
|
|
$
|
106
|
|
|
$
|
2,656
|
|
|
$
|
1,809
|
|
|
$
|
494
|
|
|
$
|
212
|
|
Interest cost
|
|
|
4,661
|
|
|
|
2,973
|
|
|
|
748
|
|
|
|
415
|
|
|
|
9,311
|
|
|
|
5,946
|
|
|
|
1,495
|
|
|
|
830
|
|
Expected return on plan assets
|
|
|
(5,821
|
)
|
|
|
(3,366
|
)
|
|
|
|
|
|
|
|
|
|
|
(11,642
|
)
|
|
|
(6,732
|
)
|
|
|
|
|
|
|
|
|
Net amortization and deferral
|
|
|
471
|
|
|
|
614
|
|
|
|
265
|
|
|
|
282
|
|
|
|
942
|
|
|
|
1,228
|
|
|
|
531
|
|
|
|
564
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Net benefit cost
|
|
$
|
641
|
|
|
$
|
1,125
|
|
|
$
|
1,260
|
|
|
$
|
803
|
|
|
$
|
1,267
|
|
|
$
|
2,251
|
|
|
$
|
2,520
|
|
|
$
|
1,606
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Note 11
|
Fair
Value Measurement
|
In September 2006, the FASB issued SFAS No. 157,
Fair Value Measurements, (SFAS 157), which is
effective for fiscal years beginning after November 15,
2007 and for interim periods within those years. This statement
defines fair value, establishes a framework for measuring fair
value and expands the related disclosure requirements. This
statement applies under other accounting pronouncements that
require or permit fair value measurements. The statement
indicates, among other things, that a fair value measurement
assumes that the transaction to sell an asset or transfer a
liability occurs in the principal market for the asset or
liability or, in the absence of a principal market, the most
advantageous market for the asset or liability. SFAS 157
defines fair value based upon an exit price model.
Relative to SFAS 157, the FASB issued
FSP 157-1
and 157-2.
FSP 157-1
amends SFAS 157 to exclude SFAS No. 13,
Accounting for Leases, (SFAS 13) and its
related interpretive accounting pronouncements that address
leasing transactions, while
FSP 157-2
delays the effective date of the application of SFAS 157 to
fiscal years beginning after November 15, 2008 for all
nonfinancial assets and nonfinancial liabilities that are
recognized or disclosed at fair value in the financial
statements on a nonrecurring basis. Non-recurring nonfinancial
assets and nonfinancial liabilities include those measured at
fair value in goodwill impairment testing, indefinite lived
intangible assets measured at fair value for impairment testing,
asset retirement obligations initially measured at fair value,
and those assets and liabilities initially measured at fair
value in a business combination.
The Company adopted SFAS 157 for financial assets and
financial liabilities as of January 1, 2008, in accordance
with the provisions of SFAS 157 and the related guidance of
FSP 157-1
and
FSP 157-2.
The adoption did not have an impact on the Companys
financial position and results of operations. The Company
endeavors to utilize the best available information in measuring
fair value. The Company has determined that its financial assets
are comprised of both Level 1 and Level 2 inputs and
that its financial liabilities are comprised of Level 2
inputs in the fair value hierarchy described as follows:
Valuation
Hierarchy
SFAS 157 establishes a valuation hierarchy for disclosure
of the inputs to valuation used to measure fair value. This
hierarchy prioritizes the inputs into three broad levels as
follows:
Level 1 inputs quoted prices (unadjusted) in
active markets for identical assets or liabilities that the
Company has ability to access at the measurement date.
17
TELEFLEX
INCORPORATED AND SUBSIDIARIES
NOTES TO
CONDENSED CONSOLIDATED FINANCIAL
STATEMENTS (Continued)
Level 2 inputs inputs other than quoted prices
included within Level 1 that are observable for the asset or
liability, either directly or indirectly. If the asset or
liability has a specified (contractual) term, a Level 2
input must be observable for substantially the full term of the
asset or liability. Level 2 inputs include:
1. Quoted prices for similar assets or liabilities in
active markets.
2. Quoted prices for identical or similar assets or
liabilities in markets that are not active or there are few
transactions.
3. Inputs other than quoted prices that are observable for
the asset or liability.
4. Inputs that are derived principally from or corroborated
by observable market data by correlation or other means.
Level 3 inputs unobservable inputs for the
asset or liability. Unobservable inputs may be used to measure
fair value only when observable inputs are not available.
Unobservable inputs reflect the Companys assumptions about
the assumptions market participants would use in pricing the
asset or liability in achieving the fair value measurement
objective of an exit price perspective.
A financial asset or liabilitys classification within the
hierarchy is determined based on the lowest level input that is
significant to the fair value measurement.
The following table provides the financial assets and
liabilities carried at fair value measured on a recurring basis
as of June 29, 2008:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Total Carrying
|
|
|
Quoted prices in
|
|
|
Significant other
|
|
|
Significant
|
|
|
|
Value at
|
|
|
active markets
|
|
|
observable inputs
|
|
|
unobservable inputs
|
|
|
|
June 29, 2008
|
|
|
(Level 1)
|
|
|
(Level 2)
|
|
|
(Level 3)
|
|
|
|
(Dollars in thousands)
|
|
|
Deferred compensation assets
|
|
$
|
3,613
|
|
|
$
|
3,613
|
|
|
$
|
|
|
|
$
|
|
|
Derivative assets
|
|
$
|
1,060
|
|
|
$
|
|
|
|
$
|
1,060
|
|
|
$
|
|
|
Derivative liabilities
|
|
$
|
18,712
|
|
|
$
|
|
|
|
$
|
18,712
|
|
|
$
|
|
|
Valuation
Techniques
The Companys financial assets valued based upon
Level 1 inputs are comprised of investments in marketable
securities held in Rabbi Trusts which are used to pay benefits
under certain deferred compensation plan benefits. Under these
deferred compensation plans, participants designate investment
options to serve as the basis for measurement of the notional
value of their accounts. The investment assets of the rabbi
trust are valued using quoted market prices multiplied by the
number of shares held in the trust.
The Companys financial assets valued based upon
Level 2 inputs are comprised of foreign currency forward
contracts. The Companys financial liabilities valued based
upon Level 2 inputs are comprised of the interest rate swap
contract and foreign currency forward contracts. The Company has
taken into account the credit worthiness of the counterparties.
The Company uses forward rate contracts to manage currency
transaction exposure and interest rate swaps to manage exposure
to interest rate changes. The fair value of the interest rate
swap contract is developed from market-based inputs under the
income approach using cash flows discounted at relevant market
interest rates. The fair value of the foreign currency forward
exchange contracts represents the amount required to enter into
offsetting contracts with similar remaining maturities based on
quoted market prices.
|
|
Note 12
|
Commitments
and contingent liabilities
|
Product warranty liability: The Company
warrants to the original purchaser of certain of its products
that it will, at its option, repair or replace, without charge,
such products if they fail due to a manufacturing defect.
Warranty periods vary by product. The Company has recourse
provisions for certain products that would enable
18
TELEFLEX
INCORPORATED AND SUBSIDIARIES
NOTES TO
CONDENSED CONSOLIDATED FINANCIAL
STATEMENTS (Continued)
recovery from third parties for amounts paid under the warranty.
The Company accrues for product warranties when, based on
available information, it is probable that customers will make
claims under warranties relating to products that have been
sold, and a reasonable estimate of the costs (based on
historical claims experience relative to sales) can be made. Set
forth below is a reconciliation of the Companys estimated
product warranty liability for the six months ended
June 29, 2008 (dollars in thousands):
|
|
|
|
|
Balance December 31, 2007
|
|
$
|
19,981
|
|
Accruals for warranties issued in 2008
|
|
|
5,360
|
|
Settlements (cash and in kind)
|
|
|
(6,708
|
)
|
Accruals related to pre-existing warranties
|
|
|
636
|
|
Effect of translation
|
|
|
48
|
|
|
|
|
|
|
Balance June 29, 2008
|
|
$
|
19,317
|
|
|
|
|
|
|
Operating leases: The Company uses various
leased facilities and equipment in its operations. The terms for
these leased assets vary depending on the applicable lease
agreement. In connection with these operating leases, the
Company had residual value guarantees in the amount of
approximately $1.9 million at June 29, 2008. The
Companys future payments under these leases cannot exceed
the minimum rent obligation plus the residual value guarantee
amount. The guarantee amounts are tied to the unamortized lease
values of the assets under lease, and are due should the Company
decide neither to renew these leases, nor to exercise its
purchase option. At June 29, 2008, the Company had no
liabilities recorded for these obligations. Any residual value
guarantee amounts paid to the lessor may be recovered by the
Company from the sale of the assets to a third party.
Accounts receivable securitization
program: The Company uses an accounts receivable
securitization program to gain access to enhanced credit markets
and reduce financing costs. As currently structured, the Company
sells certain trade receivables on a non-recourse basis to a
consolidated special purpose entity which in turn sells
interests in those receivables to a commercial paper conduit.
The conduit issues notes secured by those interests to third
party investors. The assets of the special purpose entity are
not available to satisfy our obligations. The total amount of
accounts receivable held by the special purpose entity at
June 29, 2008 and December 31, 2007 were
$158.6 million and $124.3 million, respectively. The
special purpose entity has received cash consideration of
$39.7 million for the interests in the accounts receivable
it has sold to the commercial paper conduit at each of
June 29, 2008 and December 31, 2007, which amounts
were removed from the consolidated balance sheet at such dates
in accordance with SFAS 140, Accounting for Transfers
and Servicing of Financial Assets and Extinguishments of
Liabilities.
Environmental: The Company is subject to
contingencies as a result of environmental laws and regulations
that in the future may require the Company to take further
action to correct the effects on the environment of prior
disposal practices or releases of chemical or petroleum
substances by the Company or other parties. Much of this
liability results from the U.S. Comprehensive Environmental
Response, Compensation and Liability Act (CERCLA),
often referred to as Superfund, the U.S. Resource
Conservation and Recovery Act (RCRA) and similar
state laws. These laws require the Company to undertake certain
investigative and remedial activities at sites where the Company
conducts or once conducted operations or at sites where
Company-generated waste was disposed.
Remediation activities vary substantially in duration and cost
from site to site. These activities, and their associated costs,
depend on the mix of unique site characteristics, evolving
remediation technologies, diverse regulatory agencies and
enforcement policies, as well as the presence or absence of
other potentially responsible parties. At June 29, 2008,
the Companys condensed consolidated balance sheet included
an accrued liability of approximately $8.5 million relating
to these matters. Considerable uncertainty exists with respect
to these costs and, if adverse changes in circumstances occur,
potential liability may exceed the amount accrued as of
June 29, 2008.
19
TELEFLEX
INCORPORATED AND SUBSIDIARIES
NOTES TO
CONDENSED CONSOLIDATED FINANCIAL
STATEMENTS (Continued)
The time frame over which the accrued amounts may be paid out,
based on past history, is estimated to be
15-20 years.
Regulatory matters: On October 11, 2007,
the Companys subsidiary, Arrow International, Inc.
(Arrow), received a corporate warning letter from
the U.S. Food and Drug Administration (FDA). The letter
cites three site-specific warning letters issued by the FDA in
2005 and subsequent inspections performed from June 2005 to
February 2007 at Arrows facilities in the United States.
The letter expresses concerns with Arrows quality systems,
including complaint handling, corrective and preventive action,
process and design validation, inspection and training
procedures. It also advises that Arrows corporate-wide
program to evaluate, correct and prevent quality system issues
has been deficient. Limitations on pre-market approvals and
certificates of foreign goods had previously been imposed on
Arrow based on prior inspections and the corporate warning
letter does not impose additional sanctions that are expected to
have a material financial impact on the Company.
In connection with its acquisition of Arrow, completed on
October 1, 2007, the Company developed an integration plan
that includes the commitment of significant resources to correct
these previously-identified regulatory issues and further
improve overall quality systems. Senior management officials
from the Company have met with FDA representatives, and a
comprehensive written corrective action plan was presented to
FDA in late 2007. The Company has begun implementing its
corrective action plan, which it expects to complete by the end
of 2008.
While the Company believes it can remediate these issues in an
expeditious manner, there can be no assurances regarding the
length of time or expenditures required to resolve these issues
to the satisfaction of the FDA. If the Companys remedial
actions are not satisfactory to the FDA, the Company may have to
devote additional financial and human resources to its efforts,
and the FDA may take further regulatory actions against the
Company, including, but not limited to, seizing its product
inventory, obtaining a court injunction against further
marketing of the Companys products or assessing civil
monetary penalties.
In June 2008, HM Revenue and Customs (HMRC) assessed
Airfoil Technologies International UK Limited
(ATI-UK), a consolidated United Kingdom venture in
which the Company has a 60% economic interest, approximately
$13 million for customs duty for the period from
July 1, 2005 through March 31, 2008. HMRC had
previously assessed ATI-UK approximately $1 million for
customs duty for the first and second quarters of 2004.
Additionally, for the above periods, ATI-UK was assessed a value
added tax (VAT) of approximately $93 million,
for which HMRC has advised ATI-UK that, to the extent it is due
and payable, it has until March 2010 to fully recover such VAT.
The assessments were imposed because HMRC concluded that ATI-UK
did not provide the necessary documentation for which reliance
on Inland Processing Relief status (duty and VAT) was claimed by
ATI-UK.
ATI-UK has filed an appeal and been granted a hardship
application (to avoid payment of the assessment while the appeal
is pending) regarding the assessment for the first two quarters
of 2004, and has filed an appeal and hardship application with
respect to the June 2008 assessment. ATI-UK is continuing to
assemble documentation for submission to HMRC and intends to
vigorously contest these assessments and pursue the hardship
application. In the event ATI-UK is not successful in procuring
the second hardship application or a favorable resolution of the
assessments, such outcome would have a material adverse effect
on the business of ATI-UK. The Company has a net investment in
ATI-UK of approximately $12 million.
Litigation: The Company is a party to various
lawsuits and claims arising in the normal course of business.
These lawsuits and claims include actions involving product
liability, intellectual property, employment and environmental
matters. Based on information currently available, advice of
counsel, established reserves and other resources, the Company
does not believe that any such actions are likely to be,
individually or in the aggregate, material to its business,
financial condition, results of operations or liquidity.
However, in the event of unexpected further developments, it is
possible that the ultimate resolution of these matters, or other
similar matters, if
20
TELEFLEX
INCORPORATED AND SUBSIDIARIES
NOTES TO
CONDENSED CONSOLIDATED FINANCIAL
STATEMENTS (Continued)
unfavorable, may be materially adverse to the Companys
business, financial condition, results of operations or
liquidity. Legal costs such as outside counsel fees and expenses
are charged to expense in the period incurred.
Other: The Company has various purchase
commitments for materials, supplies and items of permanent
investment incident to the ordinary conduct of business. On
average, such commitments are not at prices in excess of current
market.
|
|
Note 13
|
Business
segment information
|
Information about continuing operations by business segment is
as follows:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Three Months Ended
|
|
|
Six Months Ended
|
|
|
|
June 29,
|
|
|
July 1,
|
|
|
June 29,
|
|
|
July 1,
|
|
|
|
2008
|
|
|
2007
|
|
|
2008
|
|
|
2007
|
|
|
|
(Dollars in thousands)
|
|
|
Segment data:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Medical
|
|
$
|
384,335
|
|
|
$
|
226,428
|
|
|
$
|
758,392
|
|
|
$
|
453,317
|
|
Aerospace
|
|
|
130,140
|
|
|
|
107,347
|
|
|
|
258,838
|
|
|
|
217,604
|
|
Commercial
|
|
|
109,610
|
|
|
|
118,542
|
|
|
|
211,375
|
|
|
|
221,736
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Segment net revenues
|
|
|
624,085
|
|
|
|
452,317
|
|
|
|
1,228,605
|
|
|
|
892,657
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Medical
|
|
|
70,652
|
|
|
|
43,218
|
|
|
|
141,564
|
|
|
|
91,827
|
|
Aerospace
|
|
|
16,844
|
|
|
|
12,044
|
|
|
|
29,126
|
|
|
|
24,630
|
|
Commercial
|
|
|
9,460
|
|
|
|
10,178
|
|
|
|
12,307
|
|
|
|
15,706
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Segment operating
profit(1)
|
|
|
96,956
|
|
|
|
65,440
|
|
|
|
182,997
|
|
|
|
132,163
|
|
Less: Corporate expenses
|
|
|
10,255
|
|
|
|
12,376
|
|
|
|
22,363
|
|
|
|
23,066
|
|
Net loss on sales of businesses and assets
|
|
|
|
|
|
|
2,121
|
|
|
|
18
|
|
|
|
1,328
|
|
Restructuring and impairment charges
|
|
|
2,591
|
|
|
|
1,081
|
|
|
|
11,447
|
|
|
|
1,522
|
|
Minority interest
|
|
|
(9,098
|
)
|
|
|
(6,708
|
)
|
|
|
(16,152
|
)
|
|
|
(13,816
|
)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Income from continuing operations before interest, taxes and
minority interest
|
|
$
|
93,208
|
|
|
$
|
56,570
|
|
|
$
|
165,321
|
|
|
$
|
120,063
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
(1) |
|
Segment operating profit includes a segments net revenues
reduced by its materials, labor and other product costs along
with the segments selling, engineering and administrative
expenses and minority interest. Unallocated corporate expenses,
(gain) loss on sales of assets, restructuring and impairment
charges, interest income and expense and taxes on income are
excluded from the measure. |
|
|
Note 14
|
Divestiture-Related
Activities
|
As dispositions occur in the normal course of business, gains or
losses on the sale of such businesses are recognized in the
income statement line item Net loss on sales of
businesses and assets.
Net loss on sales of businesses and assets consists of
the following for the three and six month periods ended
June 29, 2008 and July 1, 2007:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Three Months Ended
|
|
Six Months Ended
|
|
|
June 29,
|
|
July 1,
|
|
June 29,
|
|
July 1,
|
|
|
2008
|
|
2007
|
|
2008
|
|
2007
|
|
|
(Dollars in thousands)
|
|
Net loss on sales of businesses and assets
|
|
$
|
|
|
|
$
|
2,121
|
|
|
$
|
18
|
|
|
$
|
1,328
|
|
21
TELEFLEX
INCORPORATED AND SUBSIDIARIES
NOTES TO
CONDENSED CONSOLIDATED FINANCIAL
STATEMENTS (Concluded)
During the first quarter of 2008, the Company incurred $18
thousand of additional expenses in connection with the
finalization of the sale of its ownership interest in one of its
variable interest entities.
During the first quarter of 2007, the Company sold a building
which it had classified as held for sale and realized a pre-tax
gain of $793 thousand. During the second quarter of 2007, the
Company sold a business in the Commercial Segment and realized a
pre-tax loss of $2.1 million.
Assets
Held for Sale
Assets held for sale at June 29, 2008 consists of two
buildings which the Company is actively marketing. Assets held
for sale at December 31, 2007 consisted of three buildings.
The Company sold a building in the second quarter of 2008 for
book value.
Discontinued
Operations
On December 27, 2007 the Company completed the sale of its
business units that design and manufacture automotive and
industrial driver controls, motion systems and fluid handling
systems (the GMS businesses) to Kongsberg Automotive
Holding for $560 million in cash. The sale price is subject
to adjustment based upon the working capital of the business
units included in the sale as of December 27, 2007 and
various tax elections. The Companys condensed consolidated
statement of income for the three and six month periods ended
July 1, 2007 has been retrospectively adjusted to reflect
these operations as discontinued. The divested GMS businesses
were all part of the Companys Commercial Segment.
In the second quarter of 2008, the Company refined its estimates
for the post-closing adjustments based on the provisions of the
Purchase Agreement. Also during the second quarter of 2008, the
Company recorded a charge for the settlement of a contingency
related to the sale of the GMS businesses. These activities
resulted in a decrease in the gain on sale of the GMS businesses
and are reported in discontinued operations as a loss of
$2.8 million, net of taxes of $2.0 million for the
three and six months ending June 29, 2008.
On June 29, 2007 the Company completed the sale of Teleflex
Aerospace Manufacturing Group (TAMG), a
precision-machined components business in the Aerospace Segment
for $133.9 million in cash and realized a pre-tax gain of
$75.5 million.
The results of these discontinued operations for the three and
six month periods ended July 1, 2007 were as follows:
|
|
|
|
|
|
|
|
|
|
|
Three Months Ended
|
|
|
Six Months Ended
|
|
|
|
(Dollars in thousands)
|
|
|
Net revenues
|
|
$
|
261,601
|
|
|
$
|
522,783
|
|
Costs and other expenses, net
|
|
|
168,384
|
|
|
|
411,813
|
|
|
|
|
|
|
|
|
|
|
Income from discontinued operations before income taxes
|
|
|
93,217
|
|
|
|
110,970
|
|
Provision for income taxes
|
|
|
32,602
|
|
|
|
39,912
|
|
|
|
|
|
|
|
|
|
|
Income from discontinued operations
|
|
$
|
60,615
|
|
|
$
|
71,058
|
|
|
|
|
|
|
|
|
|
|
22
|
|
Item 2.
|
Managements
Discussion and Analysis of Financial Condition and Results of
Operations
|
Forward-Looking
Statements
All statements made in this Quarterly Report on
Form 10-Q,
other than statements of historical fact, are forward-looking
statements. The words anticipate,
believe, estimate, expect,
intend, may, plan,
will, would, should,
guidance, potential,
continue, project, forecast,
confident, prospects, and similar
expressions typically are used to identify forward-looking
statements. Forward-looking statements are based on the
then-current expectations, beliefs, assumptions, estimates and
forecasts about our business and the industry and markets in
which we operate. These statements are not guarantees of future
performance and are subject to risks, uncertainties and
assumptions which are difficult to predict. Therefore, actual
outcomes and results may differ materially from what is
expressed or implied by these forward-looking statements due to
a number of factors, including changes in business relationships
with and purchases by or from major customers or suppliers,
including delays or cancellations in shipments; demand for and
market acceptance of new and existing products; our ability to
integrate acquired businesses into our operations, particularly
Arrow International Inc., realize planned synergies and operate
such businesses profitably in accordance with expectations; our
ability to effectively execute our restructuring programs;
competitive market conditions and resulting effects on revenues
and pricing; increases in raw material costs that cannot be
recovered in product pricing; and global economic factors,
including currency exchange rates and interest rates;
difficulties entering new markets; and general economic
conditions. For a further discussion of the risks relating to
our business, see Item 1A of our Annual Report on
Form 10-K
for the fiscal year ended December 31, 2007. We expressly
disclaim any obligation to update these forward-looking
statements, except as otherwise specifically stated by us or as
required by law or regulation.
Overview
Teleflex strives to maintain a portfolio of businesses that
provide consistency of performance, improved profitability and
sustainable growth. To this end, in 2007 we significantly
changed the composition of our portfolio through acquisitions
and divestitures to improve margins, reduce cyclicality and
focus our resources on the development of our core businesses.
On October 1, 2007, we acquired all of the outstanding
capital stock of Arrow International, Inc. (Arrow)
for approximately $2.1 billion including fees and expenses.
Arrow is a leading global provider of catheter-based access and
therapeutic products for critical and cardiac care. In November
2007, we acquired Nordisk Aviation Products a.s. (Nordisk), a
world leader in developing, supplying and servicing containers
and pallets for air cargo, for approximately $27.8 million,
net of cash acquired. The results of Arrow and Nordisk have been
included in our Medical and Aerospace Segments, respectively,
since their respective acquisition dates.
On June 29, 2007, we completed the sale of Teleflex
Aerospace Manufacturing Group (TAMG), a
precision-machined components business in its Aerospace Segment,
for $133.9 million in cash. On December 27, 2007, we
completed the sale of our business units that design and
manufacture automotive and industrial driver controls, motion
systems and fluid handling systems (the GMS
businesses) for $560 million in cash. The sale price
is subject to possible upward or downward adjustment based on
the working capital of the business, measured at the closing
date of the sale, and to various tax elections. In the second
quarter of 2008, we refined our estimates of the post-closing
adjustment based on the working capital of the business. In
addition, we also recorded a charge for the settlement of a
contingency related to the GMS businesses that were sold. These
activities resulted in a reduction to the gain on sale of the
GMS businesses of approximately $2.8 million, net of taxes
of $2.0 million for the three and six month periods ending
June 29, 2008 as reported in discontinued operations. For
the three and six month periods ending July 1, 2007 the
TAMG and GMS businesses have been presented in our condensed
consolidated financial statements as discontinued operations.
The Medical, Aerospace and Commercial Segments comprised 62%,
21% and 17% of our revenues, respectively, for the six months
ended June 29, 2008 and comprised 51%, 24% and 25% of our
revenues, respectively, for the same period in 2007.
23
Critical
Accounting Estimates
Preparation of our financial statements requires management to
make estimates and assumptions that affect the reported amounts
of assets, liabilities, revenues and expenses. We believe the
most complex and sensitive judgments, because of their
significance to the Consolidated Financial Statements, result
primarily from the need to make estimates about the effects of
matters that are inherently uncertain. Managements
Discussion and Analysis and Note 1 to the Consolidated
Financial Statements in our 2007 Annual Report, incorporated by
reference in our 2007
Form 10-K,
describe the significant accounting estimates and policies used
in preparation of the Consolidated Financial Statements. Actual
results in these areas could differ from managements
estimates. As discussed below and in Note 11 to the
Condensed Consolidated Financial Statements included in this
report, we have adopted Statement of Financial Accounting
Standards (SFAS) No. 157 as of January 1,
2008, with the exception of the application of the statement to
nonrecurring nonfinancial assets and nonfinancial liabilities,
the deferral of which was permitted under FASB Staff position
No. 157-2.
Other than this change, there have been no significant changes
in our critical accounting estimates during the first six months
of 2008.
In measuring fair value, we have determined that our financial
assets are comprised of both Level 1 and Level 2
inputs and that our financial liabilities are comprised of
Level 2 inputs, as defined under SFAS 157 and as
described in Note 11 to the Condensed Consolidated
Financial Statements included in this report. The counterparties
in these arrangements are major financial institutions. Although
the potential risk to us is the replacement cost of the then
estimated fair value of these instruments, management believes
that the risk of losses is remote and that the losses, if any,
would be immaterial.
Results
of Operations
We are focused on achieving consistent and sustainable growth
through the development of new products, expansion of market
share, moving existing products into new geographies, and
through selected acquisitions which enhance or expedite our
development initiatives and our ability to increase market
share. The discussion of growth from acquisitions included below
reflects the impact of a purchased company up to twelve months
beyond the date of acquisition. Activity beyond the initial
twelve months is considered core growth. Core growth excludes
the impact of translating the results of international
subsidiaries at different currency exchange rates from year to
year and the comparable activity of divested companies within
the most recent twelve-month period.
Comparison
of the three and six month periods ended June 29, 2008 and
July 1, 2007
Revenues increased approximately 38% in the second quarter of
2008 to $624.1 million from $452.3 million in the same
period of a year ago. Businesses acquired in 2007 contributed
34% to this increase in revenues and foreign currency benefited
revenue growth by 4%. Core revenue growth was flat for the
second quarter. For the first six months of 2008, revenues
increased approximately 38% to $1.2 billion from
$0.9 billion in the first six months of 2007. Businesses
acquired in the past twelve months contributed 35% to this
increase in revenues and foreign currency contributed 5% to
revenue growth, while revenues from core business declined 1%
and divestitures reduced revenues another 1%. Core revenue
decline in the first six months of 2008 was primarily due to a
significant decrease in sales volume for auxiliary power units
sold into the North American truck market, and to a lesser
extent, weaker sales of certain recreational marine products in
North America, when compared to the corresponding prior year
periods.
Gross profit as a percentage of revenues increased to 41.4% in
the second quarter of 2008 from 36.1% in the second quarter of
2007. For the first six months of 2008, gross profit as a
percentage of revenues increased to 40.0% compared to 36.4% for
the six months of 2007. For both the three month and six month
periods, the increases were largely due to the addition of
higher margin Arrow critical care product lines and improved
margins in the Aerospace Segments engine repairs business.
Selling, engineering and administrative expenses (operating
expenses) as a percentage of revenues were 26.1% for the three
months ended June 29, 2008 compared to 22.9% for the three
months ended July 1, 2007 and 25.6% for the first six
months of 2008 compared to 22.6% for the first six months of
2007, principally due to the acquisition of Arrow.
Interest expense increased significantly in the second quarter
and first six months of 2008 compared to the same periods in
2007 principally as a result of the debt incurred in connection
with the Arrow acquisition. Interest
24
income decreased in the second quarter and first six months of
2008 compared to the same periods in 2007 primarily due to lower
amounts of invested funds combined with lower average interest
rates. The effective tax rate for the three months ending
June 29, 2008 was 24.7% compared to 18.7% for the
corresponding prior year period. For the six months ending
June 29, 2008 the effective tax rate was 26.3% compared to
22.7% for the corresponding prior year period. The rate increase
in both periods reflects a higher concentration of US taxable
income in 2008 due to the Arrow acquisition and the impact of a
tax credit for research and development in 2007. Minority
interest in consolidated subsidiaries increased
$2.4 million in the second quarter and first six months of
2008 compared to the same periods in 2007 due to increased
profits during the second quarter of 2008 from consolidated
entities that are not wholly-owned.
In connection with the acquisition of Arrow, we have formulated
a plan related to the future integration of Arrow and our
Medical businesses. The integration plan focuses on the closure
of Arrow corporate functions and the consolidation of
manufacturing, sales, marketing, and distribution functions in
North America, Europe and Asia. In as much as the actions affect
employees and facilities of Arrow, the resultant costs have been
included in the allocation of the purchase price of Arrow. Costs
related to actions that affect employees and facilities of
Teleflex are charged to earnings and included in
restructuring and impairment charges within the
condensed consolidated statement of operations and amounted to
approximately $2.6 million and $11.4 million during
the three and six months ended June 29, 2008, respectively.
As of June 29, 2008, we expect to incur future
restructuring costs of between $18.4
$21.4 million when actions are taken or costs are incurred
in 2008 and 2009 in connection with this plan. Of this amount,
$6.4 $7.4 million relates to employee
termination costs, $10.5 $11.5 million relates
to lease termination costs as well as termination of certain
distribution agreements and $1.5 $2.5 million
relates to other restructuring costs. In connection with the
Arrow integration and restructuring activities, the Company has
incurred restructuring related costs in the Medical Segment
which do not qualify as restructuring costs. These costs are
reported in the results of the Medical Segments operating
profit in selling, engineering and administrative expenses.
In June 2006, we began certain restructuring initiatives that
affect all three of our operating segments. These initiatives
involve the consolidation of operations and a related reduction
in workforce at several of our facilities in Europe and North
America. We determined to undertake these initiatives to improve
operating performance and to better leverage our existing
resources. The charges, including changes in estimates,
associated with the 2006 restructuring program that are included
in restructuring and impairment charges resulted in a credit of
$143 thousand and a charge of $849 thousand for the three month
periods ended June 29, 2008 and July 1, 2007,
respectively and charges of $667 thousand and $919 thousand for
the six month periods ended June 29, 2008 and July 1,
2007, respectively. As of June 29, 2008, future
restructuring costs associated with our 2006 restructuring
program are related to contract termination costs of
approximately $266 thousand.
For additional information regarding our restructuring programs,
see Note 4 to our Condensed Consolidated Financial
statements included in this report.
25
Segment
Reviews
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Three Months Ended
|
|
|
Six Months Ended
|
|
|
|
June 29,
|
|
|
July 1,
|
|
|
% Increase/
|
|
|
June 29,
|
|
|
July 1,
|
|
|
% Increase/
|
|
|
|
2008
|
|
|
2007
|
|
|
(Decrease)
|
|
|
2008
|
|
|
2007
|
|
|
(Decrease)
|
|
|
|
|
|
|
|
|
|
(Dollars in thousands)
|
|
|
|
|
|
|
|
|
Segment data:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Medical
|
|
$
|
384,335
|
|
|
$
|
226,428
|
|
|
|
70
|
|
|
$
|
758,392
|
|
|
$
|
453,317
|
|
|
|
67
|
|
Aerospace
|
|
|
130,140
|
|
|
|
107,347
|
|
|
|
21
|
|
|
|
258,838
|
|
|
|
217,604
|
|
|
|
19
|
|
Commercial
|
|
|
109,610
|
|
|
|
118,542
|
|
|
|
(8
|
)
|
|
|
211,375
|
|
|
|
221,736
|
|
|
|
(5
|
)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Segment net revenues
|
|
|
624,085
|
|
|
|
452,317
|
|
|
|
38
|
|
|
|
1,228,605
|
|
|
|
892,657
|
|
|
|
38
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Medical
|
|
|
70,652
|
|
|
|
43,218
|
|
|
|
64
|
|
|
|
141,564
|
|
|
|
91,827
|
|
|
|
54
|
|
Aerospace
|
|
|
16,844
|
|
|
|
12,044
|
|
|
|
40
|
|
|
|
29,126
|
|
|
|
24,630
|
|
|
|
18
|
|
Commercial
|
|
|
9,460
|
|
|
|
10,178
|
|
|
|
(7
|
)
|
|
|
12,307
|
|
|
|
15,706
|
|
|
|
(22
|
)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Segment operating profit
|
|
$
|
96,956
|
|
|
$
|
65,440
|
|
|
|
48
|
|
|
$
|
182,997
|
|
|
$
|
132,163
|
|
|
|
39
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
The percentage increases or (decreases) in net revenues during
the three and six month periods ended June 29, 2008
compared to the same period in 2007 are due to the following
factors:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
% Increase/(Decrease)
|
|
|
|
2008 vs. 2007
|
|
|
|
Medical
|
|
|
Aerospace
|
|
|
Commercial
|
|
|
Total
|
|
|
|
Three
|
|
|
Six
|
|
|
Three
|
|
|
Six
|
|
|
Three
|
|
|
Six
|
|
|
Three
|
|
|
Six
|
|
|
|
Months
|
|
|
Months
|
|
|
Months
|
|
|
Months
|
|
|
Months
|
|
|
Months
|
|
|
Months
|
|
|
Months
|
|
|
Acquisitions
|
|
|
62
|
|
|
|
61
|
|
|
|
12
|
|
|
|
12
|
|
|
|
3
|
|
|
|
5
|
|
|
|
34
|
|
|
|
35
|
|
Core growth
|
|
|
3
|
|
|
|
1
|
|
|
|
5
|
|
|
|
4
|
|
|
|
(11
|
)
|
|
|
(11
|
)
|
|
|
|
|
|
|
(1
|
)
|
Currency impact
|
|
|
6
|
|
|
|
6
|
|
|
|
4
|
|
|
|
3
|
|
|
|
1
|
|
|
|
2
|
|
|
|
4
|
|
|
|
5
|
|
Dispositions
|
|
|
(1
|
)
|
|
|
(1
|
)
|
|
|
|
|
|
|
|
|
|
|
(1
|
)
|
|
|
(1
|
)
|
|
|
|
|
|
|
(1
|
)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Total Change
|
|
|
70
|
|
|
|
67
|
|
|
|
21
|
|
|
|
19
|
|
|
|
(8
|
)
|
|
|
(5
|
)
|
|
|
38
|
|
|
|
38
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
The following is a discussion of our segment operating results.
Comparison
of the three and six month periods ended June 29, 2008 and
July 1, 2007
Medical
Medical Segment net revenues grew 70% in the second quarter of
2008 to $384.3 million, from $226.4 million in the
same period last year. The acquisition of Arrow accounted for
$139.0 million, or 62%, of this increase in revenues. Of
the remaining 8% increase in net revenues, 6%was due to foreign
currency fluctuations and 3% was due to core revenue growth,
partially offset by a 1% impact from divestitures. Medical
segment core revenue growth in the second quarter reflected
higher sales volume for critical care and surgical products in
Europe and an increase in sales of orthopedic and specialty
medical devices to original equipment manufacturers when
compared to the same period in 2007.
26
Medical Segment net revenues include sales of critical care,
surgical and cardiac care products as well as sales of medical
devices to original equipment manufacturers. Net sales by
product group are comprised of the following:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Three Months Ended
|
|
|
Six Months Ended
|
|
|
|
June 29,
|
|
|
July 1,
|
|
|
% Increase/
|
|
|
June 29,
|
|
|
July 1,
|
|
|
% Increase/
|
|
|
|
2008
|
|
|
2007
|
|
|
(Decrease)
|
|
|
2008
|
|
|
2007
|
|
|
(Decrease)
|
|
|
|
|
|
|
|
|
|
(Dollars in millions)
|
|
|
|
|
|
|
|
|
Critical Care
|
|
$
|
243.3
|
|
|
$
|
115.9
|
|
|
|
110
|
|
|
$
|
480.5
|
|
|
$
|
231.4
|
|
|
|
108
|
|
Surgical
|
|
|
77.5
|
|
|
|
71.7
|
|
|
|
8
|
|
|
|
148.3
|
|
|
|
141.9
|
|
|
|
5
|
|
Cardiac Care
|
|
|
19.1
|
|
|
|
|
|
|
|
100
|
|
|
|
40.8
|
|
|
|
|
|
|
|
100
|
|
OEM
|
|
|
40.8
|
|
|
|
35.7
|
|
|
|
14
|
|
|
|
78.8
|
|
|
|
70.3
|
|
|
|
12
|
|
Other
|
|
|
3.6
|
|
|
|
3.1
|
|
|
|
16
|
|
|
|
10.0
|
|
|
|
9.7
|
|
|
|
3
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Total Sales
|
|
$
|
384.3
|
|
|
$
|
226.4
|
|
|
|
70
|
|
|
$
|
758.4
|
|
|
$
|
453.3
|
|
|
|
67
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
The Arrow acquisition contributed a total of $139.0 million
and $273.5 million to Medical Segment revenues for the
three and six month periods ended June 29, 2008,
respectively, of which $119.9 million and
$232.7 million are included in the critical care product
group and $19.1 million and $40.8 million are included
in the cardiac care product category for the three and six month
periods ended June 29, 2008, respectively.
Medical Segment net revenues include sales of critical care,
surgical and cardiac care products to hospitals and healthcare
providers, which represents 90% of the Medical Segments
net revenues for the first six months of 2008 and are
geographically comprised of the following:
|
|
|
|
|
North America
|
|
|
44
|
%
|
Europe, Middle East and Africa
|
|
|
36
|
%
|
Asia and Latin America
|
|
|
10
|
%
|
|
|
|
|
|
|
|
|
90
|
%
|
|
|
|
|
|
The remaining 10% of the Medical Segments net revenues are
derived from sales of medical devices to original equipment
manufacturers.
Critical care product sales increased during the second quarter
as compared to the corresponding prior year period. This
increase was primarily due to the acquisition of Arrow in the
fourth quarter of 2007, which expanded our vascular access and
regional anesthesia product lines and contributed
$119.9 million to the critical care category during the
quarter. Critical care sales of respiratory products increased
on favorable foreign currency and stronger sales volume in
Europe and Asia/Latin America, while sales of respiratory care
products in North America markets declined compared to the
corresponding prior year quarter. Anesthesia sales increased in
North America due to higher volume and in Europe on favorable
foreign currency related to higher volume while sales in
Asia/Latin America declined slightly compared to the
corresponding prior year quarter, largely as a result of price
pressure for certain airway management products. Urology product
sales increased due to higher volume on sales in Europe and
Asia/Latin America, partially offset by a slight decline in
North America. For the first six months of 2008, critical care
product sales increased compared to the same period of a year
ago primarily due to the addition of the Arrow products
($232.7 million). Other factors that account for the
remaining $16.4 million of sales growth during the six
months ended June 29, 2008 include favorable foreign
currency translation and increased volume for respiratory and
urology products in Europe and Asia/Latin America.
Surgical product sales increased approximately 8% during the
second quarter of 2008 compared to the same period of a year ago
benefiting from favorable foreign currency translation and
higher volumes for certain product lines. Increased sales of
surgical products in European markets were partially offset by
declines in surgical device sales in North America compared to
the corresponding prior year quarter. This decline was primarily
in the chest drainage and instrumentation product lines. For the
first six months of 2008, surgical product sales increased 5%,
largely as a result of favorable foreign currency and higher
volume for surgical products in European markets.
27
Cardiac care product sales increased as a result of the Arrow
acquisition in the fourth quarter of 2007, which added
$19.1 million and $40.8 million in revenues for this
product category in the three and six month periods ended
June 29, 2008, respectively.
Sales to original equipment manufacturers increased during the
second quarter primarily as a result of increased sales of
orthopedic instrumentation when compared to the corresponding
prior year quarter and higher volumes for specialty suture
products. For the first six months of 2008, sales to original
equipment manufacturers increased primarily as a result of an
acquisition in the orthopedic product line in early 2007,
increased sales of orthopedic instrumentation and higher volumes
for specialty sutures and other devices.
Operating profit in the Medical Segment increased 64% during the
second quarter of 2008 to $70.7 million, from
$43.2 million in the corresponding prior year period. For
the first six months of 2008, segment operating profit increased
54% to $141.6 million, from $91.8 million in the
corresponding prior year period. For both periods, the addition
of higher margin Arrow critical care product lines was the
principal factor that caused the higher segment operating
profit. Other factors that contributed to the higher operating
profit were improved cost and operational efficiencies, higher
volumes in Europe and the favorable impact from the
strengthening Euro.
Aerospace
Aerospace Segment revenues grew 21% in the second quarter of
2008 to $130.1 million, from $107.3 million in the
corresponding prior year period. The expansion of the cargo
containers product line with the acquisition of Nordisk Aviation
Products contributed approximately 12% of this growth. Foreign
currency fluctuations and core growth contributed approximately
4% and 5%, respectively. The increase in core revenues reflects
a significant increase in unit volume for narrow body
cargo-loading systems and for cargo aftermarket spare components
and repairs which more than offset lower volumes for cargo
containers and actuators. Core revenues from engine repair
products and services increased slightly compared to the
corresponding prior year quarter. For the first six months of
2008 Aerospace revenues grew 19% to $258.8 million, from
$217.6 million in the corresponding prior year period. This
growth was principally due to the impact of the Nordisk
acquisition and increased sales of wide body cargo handling
systems, narrow body cargo loading systems and spare components
and repairs.
Segment operating profit increased 40% in the second quarter of
2008 to $16.8 million, from $12.0 million in the
corresponding prior year period. For the first six months of
2008, segment operating profit increased 18% to
$29.1 million compared to $24.6 million in the
corresponding prior year period. For both periods, the increase
was principally due to the impact of the Nordisk acquisition,
favorable product mix in the engine repair services business
resulting from higher volume for engine repair and lower demand
for replacement parts compared to the corresponding prior year
period and from consolidation of operations and phasing out of
lower margin product lines in the engine repair services
business during 2007.
Commercial
Commercial Segment revenues declined approximately 8% in the
second quarter of 2008 to $109.6 million, from
$118.5 million in the same period last year. Core growth of
12% in sales of rigging services products was more than offset
by lower sales of auxiliary power units for the North American
truck market and lower sales of marine products resulting in an
overall decline in core revenue of 11% in the Commercial
Segment. An acquisition in the rigging services business
contributed 3% growth and foreign currency contributed 1%,
partially offset by dispositions of 1%. For the first six months
of 2008 Commercial revenues declined 5% to $211.4 million,
from $221.7 million during the corresponding prior year
period as a result of a decline in sales of auxiliary power
units for the North American truck market and to a lesser extent
a decline in sales of marine products for the recreational boat
market.
During the second quarter of 2008, operating profit in the
Commercial Segment declined 7% to $9.5 million, from
$10.2 million in the corresponding prior year period. For
the first six months of 2008, segment operating profit declined
22% to $12.3 million compared to $15.7 million in the
corresponding prior year period. The decline in operating profit
for both periods was principally due to unfavorable foreign
currency impacts, lower volumes in the power systems and marine
businesses, which more than offset the positive impact of
increased volume and favorable product mix in the rigging
services business compared to the corresponding prior year
periods.
28
Liquidity
and Capital Resources
Operating activities from continuing operations provided net
cash of approximately $22.0 million during the first six
months of 2008. Operating assets and liabilities decreased
$119.1 million during the first six months of 2008
primarily due to approximately $90.2 million of estimated
tax payments made in connection with businesses divested during
the fourth quarter of 2007. Our financing activities from
continuing operations during the first six months of 2008
consisted primarily of repayment of long-term debt of
approximately $39.0 million, payment of dividends of
$26.1 million and payments to minority interest
shareholders of $24.9 million. Our investing activities
from continuing operations during the first six months of 2008
consisted primarily of capital expenditures of
$17.8 million and $5.7 million of additional payments
for businesses acquired primarily Nordisk. Cash flows used in
discontinued operations of $5.6 million reflects the
settlement of a contingency related to the sale of the GMS
businesses.
We use an accounts receivable securitization program to gain
access to enhanced credit markets and reduce financing costs. As
currently structured, we sell certain trade receivables on a
non-recourse basis to a consolidated special purpose entity
which in turn sells interests in those receivables to a
commercial paper conduit. The conduit issues notes secured by
those interests to third party investors. The assets of the
special purpose entity are not available to satisfy our
obligations. The total amount of accounts receivable held by the
special purpose entity at June 29, 2008 and
December 31, 2007 were $158.6 million and
$124.3 million, respectively.
The special purpose entity has received cash consideration of
$39.7 million for the interests in the accounts receivable
it has sold to the commercial paper conduit at each of
June 29, 2008 and December 31, 2007 which amounts were
removed from the consolidated balance sheet at such dates in
accordance with SFAS 140, Accounting for Transfers
and Servicing of Financial Assets and Extinguishments of
Liabilities.
On June 14, 2007, our Board of Directors authorized the
repurchase of up to $300 million of our outstanding common
stock. Repurchases of our stock under the Board authorization
may be made from time to time in the open market and may include
privately-negotiated transactions as market conditions warrant
and subject to regulatory considerations. The stock repurchase
program has no expiration date and our ability to execute on the
program will depend on, among other factors, cash requirements
for acquisitions, cash generation from operations, debt
repayment obligations, market conditions and regulatory
requirements. In addition, under the senior loan agreements
entered into October 1, 2007, we are subject to certain
restrictions relating to our ability to repurchase shares in the
event our consolidated leverage ratio exceeds certain levels,
which may further limit our ability to repurchase shares under
this Board authorization. Through June 29, 2008, no shares
have been purchased under this Board authorization.
The following table provides our net debt to total capital ratio:
|
|
|
|
|
|
|
|
|
|
|
June 29,
|
|
|
December 31,
|
|
|
|
2008
|
|
|
2007
|
|
|
|
(Dollars in thousands)
|
|
|
Net debt includes:
|
|
|
|
|
|
|
|
|
Current borrowings
|
|
$
|
172,491
|
|
|
$
|
185,129
|
|
Long-term borrowings
|
|
|
1,473,545
|
|
|
|
1,499,130
|
|
|
|
|
|
|
|
|
|
|
Total debt
|
|
|
1,646,036
|
|
|
|
1,684,259
|
|
Less: Cash and cash equivalents
|
|
|
103,242
|
|
|
|
201,342
|
|
|
|
|
|
|
|
|
|
|
Net debt
|
|
$
|
1,542,794
|
|
|
$
|
1,482,917
|
|
|
|
|
|
|
|
|
|
|
Total capital includes:
|
|
|
|
|
|
|
|
|
Net debt
|
|
$
|
1,542,794
|
|
|
$
|
1,482,917
|
|
Shareholders equity
|
|
|
1,394,484
|
|
|
|
1,328,843
|
|
|
|
|
|
|
|
|
|
|
Total capital
|
|
$
|
2,937,278
|
|
|
$
|
2,811,760
|
|
|
|
|
|
|
|
|
|
|
Percent of net debt to total capital
|
|
|
53
|
%
|
|
|
53
|
%
|
29
As of June 29, 2008, the aggregate amount of debt maturing
for each year is as follows (dollars in millions):
|
|
|
|
|
Remaining 2008
|
|
$
|
146.9
|
|
2009
|
|
|
103.5
|
|
2010
|
|
|
102.2
|
|
2011
|
|
|
247.2
|
|
2012
|
|
|
819.7
|
|
2013 and thereafter
|
|
|
226.5
|
|
The aggregate amount of debt maturing in 2008 as of
June 29, 2008 includes $42.7 million outstanding under
a revolving line of credit. This credit facility is committed
for five years from October 1, 2007.
We believe that our cash flow from operations and our ability to
access additional funds through credit facilities will enable us
to fund our operating requirements and capital expenditures and
meet debt obligations.
|
|
Item 3.
|
Quantitative
and Qualitative Disclosures About Market Risk
|
There have been no significant changes in market risk for the
quarter ended June 29, 2008 from those addressed in the
Companys Annual Report on
Form 10-K
for the fiscal year ended December 31, 2007. See the
information set forth in Part II, Item 7A of the
Companys Annual Report on
Form 10-K
for the fiscal year ended December 31, 2007.
|
|
Item 4.
|
Controls
and Procedures
|
(a) Evaluation of Disclosure Controls and Procedures
Our management, with the participation of our Chief Executive
Officer and Chief Financial Officer, evaluated the effectiveness
of our disclosure controls and procedures as of the end of the
period covered by this report. Based on that evaluation, the
Chief Executive Officer and Chief Financial Officer concluded
that our disclosure controls and procedures as of the end of the
period covered by this report are functioning effectively to
provide reasonable assurance that the information required to be
disclosed by us in reports filed under the Securities Exchange
Act of 1934 is (i) recorded, processed, summarized and
reported within the time periods specified in the SECs
rules and forms and (ii) accumulated and communicated to
our management, including the Chief Executive Officer and Chief
Financial Officer, as appropriate to allow timely decisions
regarding disclosure. A controls system cannot provide absolute
assurance that the objectives of the controls system are met,
and no evaluation of controls can provide absolute assurance
that all control issues and instances of fraud, if any, within a
company have been detected.
(b) Change in Internal Control over Financial Reporting
No change in our internal control over financial reporting
occurred during our most recent fiscal quarter that has
materially affected, or is reasonably likely to materially
affect, our internal control over financial reporting.
30
PART II
OTHER INFORMATION
|
|
Item 1.
|
Legal
Proceedings
|
On October 11, 2007, the Companys subsidiary, Arrow
International, Inc. (Arrow), received a corporate
warning letter from the U.S. Food and Drug Administration
(FDA). The letter cites three site-specific warning letters
issued by the FDA in 2005 and subsequent inspections performed
from June 2005 to February 2007 at Arrows facilities in
the United States. The letter expresses concerns with
Arrows quality systems, including complaint handling,
corrective and preventive action, process and design validation,
inspection and training procedures. It also advises that
Arrows corporate-wide program to evaluate, correct and
prevent quality system issues has been deficient. Limitations on
pre-market approvals and certificates of foreign goods had
previously been imposed on Arrow based on prior inspections and
the corporate warning letter does not impose additional
sanctions that are expected to have a material financial impact
on the Company.
In connection with its acquisition of Arrow, completed on
October 1, 2007, the Company has developed an integration
plan that includes the commitment of significant resources to
correct these previously-identified regulatory issues and
further improve overall quality systems. Senior management
officials from the Company have met with FDA representatives,
and a comprehensive written corrective action plan was presented
to FDA in late 2007. The Company has begun implementing its
corrective action plan, which it expects to complete by the end
of 2008.
While the Company believes it can remediate these issues in an
expeditious manner, there can be no assurances regarding the
length of time or cost it will take the Company to resolve these
issues to the satisfaction of the FDA. If the Companys
remedial actions are not satisfactory to the FDA, it may have to
devote additional financial and human resources to its efforts,
and the FDA may take further regulatory actions against the
Company, including, but not limited to, seizing its product
inventory, obtaining a court injunction against further
marketing of the Companys products or assessing civil
monetary penalties.
In June 2008, HM Revenue and Customs (HMRC) assessed
Airfoil Technologies International UK Limited
(ATI-UK), a consolidated United Kingdom venture in
which the Company has a 60% economic interest, approximately
$13 million for customs duty for the period from
July 1, 2005 through March 31, 2008. HMRC had
previously assessed ATI-UK approximately $1 million for
customs duty for the first and second quarters of 2004.
Additionally, for the above periods, ATI-UK was assessed a value
added tax (VAT) of approximately $93 million,
for which HMRC has advised ATI-UK that, to the extent it is due
and payable, it has until March 2010 to fully recover such VAT.
The assessments were imposed because HMRC concluded that ATI-UK
did not provide the necessary documentation for which reliance
on Inland Processing Relief status (duty and VAT) was claimed by
ATI-UK.
ATI-UK has filed an appeal and been granted a hardship
application (to avoid payment of the assessment while the appeal
is pending) regarding the assessment for the first two quarters
of 2004, and has filed an appeal and hardship application with
respect to the June 2008 assessment. ATI-UK is continuing to
assemble documentation for submission to HMRC and intends to
vigorously contest these assessments and pursue the hardship
application. In the event ATI-UK is not successful in procuring
the second hardship application or a favorable resolution of the
assessments, such outcome would have a material adverse effect
on the business of ATI-UK. The Company has a net investment in
ATI-UK of approximately $12 million.
In addition, the Company is a party to various lawsuits and
claims arising in the normal course of business. These lawsuits
and claims include actions involving product liability,
intellectual property, employment and environmental matters.
Based on information currently available, advice of counsel,
established reserves and other resources, the Company does not
believe that any such actions are likely to be, individually or
in the aggregate, material to its business, financial condition,
results of operations or liquidity. However, in the event of
unexpected further developments, it is possible that the
ultimate resolution of these matters, or other similar matters,
if unfavorable, may be materially adverse to the Companys
business, financial condition, results of operations or
liquidity.
31
There have been no significant changes in risk factors for the
quarter ended June 29, 2008 from those addressed in the
Companys Annual Report on
Form 10-K
for the fiscal year ended December 31, 2007. See the
information set forth in Part I, Item 1A of the
Companys Annual Report on
Form 10-K
for the fiscal year ended December 31, 2007.
|
|
Item 2.
|
Unregistered
Sales of Equity Securities and Use of Proceeds
|
Not applicable.
|
|
Item 3.
|
Defaults
Upon Senior Securities
|
Not applicable.
|
|
Item 4.
|
Submission
of Matters to a Vote of Security Holders
|
At the Companys 2008 Annual Meeting of Stockholders held
on May 1, 2008, the Companys stockholders voted on:
|
|
|
|
|
the election of four directors of the Company to serve for a
term of three years or until their successors have been elected
and qualified;
|
|
|
|
a proposal to approve the Companys 2008 Stock Incentive
Plan; and
|
|
|
|
a proposal to ratify the appointment of PricewaterhouseCoopers
LLP as the Companys independent registered public
accounting firm for the 2008 fiscal year.
|
With respect to the election of directors, the Companys
stockholders elected each of George Babich, Jr., William R.
Cook, Stephen K. Klasko and Benson F. Smith to the
Companys Board of Directors to serve a three-year term
expiring in 2011. The number of votes cast for or withheld with
respect to each nominee is set forth below:
|
|
|
|
|
|
|
|
|
Name
|
|
For
|
|
|
Withheld
|
|
|
George Babich, Jr.
|
|
|
34,375,719
|
|
|
|
995,149
|
|
William R. Cook
|
|
|
34,389,175
|
|
|
|
981,693
|
|
Stephen K. Klasko
|
|
|
34,343,638
|
|
|
|
1,027,230
|
|
Benson F. Smith
|
|
|
34,143,583
|
|
|
|
1,227,285
|
|
The directors of the Company comprising the other two classes of
the Board, who continued in office following the meeting, are
Jeffrey P. Black, Sigismundus W.W. Lubsen, Judith M. von
Seldeneck and Harold L. Yoh III, whose terms expire in 2009, and
Patricia C. Barron, Jeffrey A. Graves and James W. Zug, whose
terms expire in 2010.
With respect to the remaining proposals, the Companys
stockholders approved the Companys 2008 Stock Incentive
Plan and ratified the appointment of PricewaterhouseCoopers LLP
as the Companys independent registered public accounting
firm for the 2008 fiscal year. The number of votes cast for or
against, the number of abstentions and the number of broker
non-votes with respect to each proposal is set forth below:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Proposal
|
|
For
|
|
Against
|
|
Abstain
|
|
Broker Non-Votes
|
|
Approval of 2008 Stock Incentive Plan
|
|
|
24,577,191
|
|
|
|
7,039,982
|
|
|
|
516,413
|
|
|
|
3,237,283
|
|
Ratification of the appointment of PricewaterhouseCoopers LLP as
the Companys independent registered public accounting firm
for the 2008 fiscal year
|
|
|
34,815,245
|
|
|
|
524,369
|
|
|
|
31,254
|
|
|
|
|
|
|
|
Item 5.
|
Other
Information
|
Not applicable.
32
The following exhibits are filed as part of this report:
|
|
|
|
|
|
|
Exhibit No.
|
|
|
|
Description
|
|
|
31
|
.1
|
|
|
|
Certification of Chief Executive Officer pursuant to
Rule 13a 14(a) under the Securities Exchange
Act of 1934.
|
|
31
|
.2
|
|
|
|
Certification of Chief Financial Officer pursuant to
Rule 13a 14(a) under the Securities Exchange
Act of 1934.
|
|
32
|
.1
|
|
|
|
Certification of Chief Executive Officer pursuant to
Rule 13a 14(b) under the Securities Exchange
Act of 1934.
|
|
32
|
.2
|
|
|
|
Certification of Chief Financial Officer, Pursuant to
Rule 13a 14(b) under the Securities Exchange
Act of 1934.
|
33